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A B S T R A C T
Background
Most liver transplant recipients receive either cyclosporin or tacrolimus to prevent rejection. Both drugs inhibit calcineurin phosphatase
which is thought to be the mechanism of their anti-rejection effect and principle toxicities. The drugs have different pharmacokinetic
profiles and potencies. Several randomised clinical trials have compared cyclosporin and tacrolimus in liver transplant recipients, but
it remains unclear which is superior.
Objectives
To evaluate the beneficial and harmful effects of immunosuppression with cyclosporin versus tacrolimus for liver transplanted patients.
Search strategy
The Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials in The Cochrane Library,
MEDLINE,EMBASE, and Science Citation Index Expanded, and conference proceedingswere searched (August 2005) to identify relevant
randomised clinical trials. Our search included scanning of reference lists in relevant articles and correspondence with investigators and
pharmaceutical companies.
Selection criteria
All randomised clinical trials where tacrolimus was compared with cyclosporin for the initial treatment of first-time liver transplant
recipients. We included randomised trials irrespective of blinding, language, and publication status.
Data collection and analysis
The primary outcome measure was all-cause mortality. Data were synthesised (fixed-effect model) and results expressed as relative risk
(RR), values less than 1.0 favouring tacrolimus, with 95% confidence intervals (CI). Two authors assessed trials for eligibility, quality,
and extracted data independently.
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Main results
We included 16 randomised trials. The number of deaths was 254 in the tacrolimus group (1899 patients) and 302 in the cyclosporin
group (1914 patients). At one year, mortality (RR 0.85, 95% CI 0.73 to 0.99) and graft loss (RR 0.73, 95% CI 0.61 to 0.86) were
significantly reduced in tacrolimus-treated recipients. Tacrolimus reduced the number of recipients with acute rejection (RR 0.81, 95%
CI 0.75 to 0.88), and steroid-resistant rejection (RR 0.54, 95% CI 0.47 to 0.74) in the first year. Differences were not seen with respect
to lymphoproliferative disorder or de-novo dialysis rates, but more de-novo insulin-requiring diabetes mellitus (RR 1.38, 95% CI 1.01
to 1.86) occurred in the tacrolimus group. More patients were withdrawn from cyclosporin therapy than from tacrolimus (RR 0.57,
95% CI 0.49 to 0.66).
Authors’ conclusions
Tacrolimus is superior to cyclosporin in improving survival (patient and graft) and preventing acute rejection after liver transplantation,
but it increases the risk of post-transplant diabetes. Treating 100 recipients with tacrolimus instead of cyclosporin would avoid acute
rejection and steroid-resistant rejection in nine and seven patients, respectively, and graft loss and death in five and two patients,
respectively, but four additional patients would develop diabetes after liver transplantation.
P L A I N L A N G U A G E S U M M A R Y
Tacrolimus is superior to cyclosporin in improving patient survival, graft survival, and in preventing acute rejection after liver
transplantation, but increases post-transplant diabetes
Almost every liver transplant recipient takes either cyclosporin or tacrolimus to prevent rejection of the graft. This is a review of the
clinical trials that compared patients initially prescribed one of the two anti-rejection drugs after liver transplantation. Sixteen trials
(3813 participants) were included. The review shows that tacrolimus is marginally better than cyclosporin at preventing patient death
and graft loss. Tacrolimus is substantially better than cyclosporin at preventing rejection. No differences were seen between the drugs
with respect to adverse events (renal failure, lymphoproliferative disorder) except for diabetes mellitus, which was more common with
tacrolimus. After liver transplantation more patients stayed on tacrolimus than on cyclosporin. Tacrolimus is more beneficial than
cyclosporine and should be considered the treatment of choice after liver transplantation. This review does not evaluate the benefit or
harm of switching from one anti-rejection drug to another.
B A C K G R O U N D
Cyclosporin was introduced as primary immunosuppressant af-
ter liver transplantation instead of azathioprine over 20 years ago
without testing in randomised clinical trials because of perceived
transparent benefit (Starzl 1985). About 10 years ago, the first
randomised clinical trials of immunosuppression after liver trans-
plantation compared tacrolimus versus cyclosporin. Two large reg-
istration trials showed a reduction in the rate of acute rejection
with tacrolimus, but reductions in post-transplantation mortality
and graft loss were not statistically significant (European Study
1994; U. S. Study 1994). Subsequently both tacrolimus and cy-
closporin were found to have a common mechanism of action (ie,
inhibition of calcineurin phosphatase) even though they bound
different intra-cellular proteins. These intra-cellular proteins be-
long to the immunophilin family. Cyclosporin binds cyclophilin
and tacrolimus binds FKBP12 (Siekierka 1992). The role of im-
munophilin binding in the mechanism of toxicity is not clear, but
it may allow for a different side effect profile of these drugs, which
are now known as calcineurin inhibitors. For instance, cyclosporin
is known to cause hirsuitism whereas tacrolimus either has no ef-
fect or causes hair loss. Therefore, cyclosporin and tacrolimus may
have different benefit and harm profiles, but to date randomised
clinical trials have not shown statistically significant differences in
major outcomes after liver transplantation. A systematic review
of cyclosporin versus tacrolimus for kidney transplanted patients
has been conducted (Knoll 1999;Webster 2005), but we have not
identified previous meta-analyses or systematic reviews for liver
2Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
transplanted patients (Knoll 1999).
O B J E C T I V E S
To evaluate the beneficial and harmful effects of immunosuppres-
sion with cyclosporin versus tacrolimus for liver transplanted pa-
tients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised clinical trials were included irrespective of language
or publication status (ie, unpublished trials, abstracts, or full paper
articles).
Types of participants
We included patients undergoing their first liver transplantation.
Patients were excluded if they were undergoing multi-organ trans-
plantation, had previously received a liver transplant, or were re-
ceiving an ABO-incompatible transplant.
Types of interventions
We included randomised comparisons of tacrolimus versus cy-
closporin. The dose and duration of therapy were considered in
our inclusion criteria, but were to be evaluated in subgroup anal-
yses. Collateral interventions were allowed if received by all inter-
vention arms with the exception of azathioprine administration,
which was to be evaluated in subgroup analyses.
Types of outcome measures
The following outcome measures were evaluated one year after
randomisation.
(1) All-cause mortality (primary outcome measure)
(2) Graft loss
(3) Rejection
(4) Steroid-resistant rejection (as defined by each study)
(5) New-onset diabetes (as defined by each study)
(6) New-onset dialysis-dependent renal failure
(7) Post-transplant lymphoproliferative disease
(8) Dose reductions due to adverse events
(9) Withdrawals and dropouts.
In studies where one year follow-up was not available even after
correspondence with the principal investigator, those outcomes
that are available at the nearest time point to one yearwere included
in the general and sub-group analyses.
Search methods for identification of studies
S Klingenberg, the Trials Search Coordinator, performed elec-
tronic searches using search strategies as revised by the authors. E
Haddad and V McAlister evaluated whether these trials fulfilled
the inclusion criteria. The search results and selections were mon-
itored by all authors.
The Cochrane Hepato-Biliary Group Controlled Trials Register (Au-
gust 2005), theCochrane Central Register of Controlled Trials (CEN-
TRAL) in The Cochrane Library (Issue 3, 2005), MEDLINE (1950
to August 2005), EMBASE (1980 to August 2005), and Science
Citation Index Exapanded (1945 to August 2005) (Royle 2003)
were searched using the strategies as described in Appendix 1. E
Renouf scanned bibliographies in relevant articles and conference
proceedings (Transplantation Society biannual meetings 1988 to
2004; International Liver Transplantation Society Congress 1995
to 2004). V McAlister wrote to authors of included trials and
pharmaceutical companies that are involved in the production of
tacrolimus or cyclosporin.
Data collection and analysis
The present reviewwas performed following the recommendations
of The Cochrane Collaboration (Higgins 2005). Identified trials
were listed and their fulfilment of the inclusion criteria assessed
by V McAlister. Excluded trials were listed with the reason for
exclusion.
Data extraction
E Haddad and V McAlister independently extracted data using
standardised extraction forms. E Renouf prepared copies of the
reports that were blinded with regard to place of publication, au-
thors, and their affiliation for the primary data extraction process.
Data extraction results were monitored by all authors. Disagree-
ments were resolved by discussion. V McAlister wrote to investi-
gators and to the sponsoring companies of included trials to ask
for data that were not presented in the published reports.
From each trial, we extracted the following characteristics of the
included:
• Patients (inclusions and exclusion criteria, mean age,
proportion of men, aetiology of liver disease, creatinine pre-op
and at one year;
• Interventions (dose and duration, concomitant therapy,
maintenance drug dose, maintenance drug level);
• Trials (setting, methodological quality, publication status,
duration of follow-up, and all outcomes).
Methodological quality
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Randomisation and follow-up were extracted as measures of
methodological quality (Kjaergard 2001) using the definitions
listed below.
Generation of the allocation sequence
This is the procedure used to create a random sequence ensuring
that each patient has a known, unpredictable, and usually equal
chance of being assigned to intervention groups. The allocation
sequence generation was classified as adequate (if the allocation
sequence was generated by a computer or random number table),
unclear (if the trial was described as randomised, but the method
used for the allocation sequence generation was not described),
or inadequate (if a system involving dates, names, or admittance
numbers were used).
Allocation concealment
This is the procedure used to conceal the allocation sequence from
the investigators who assign patients to the intervention groups.
The allocation concealment was classified as adequate (if the al-
location of patients involved a central independent unit, sealed
envelopes, on-site locked computer, or identically appearing num-
bered drug bottles or containers prepared by an independent phar-
macist), unclear (if the trial was described as randomised, but the
method used to conceal the allocation was not described), or in-
adequate (if the trial was quasi-randomised).
Blinding
Considering the nature of the intervention, we expected that none
of the eligible trials will be double blind. Blinding was therefore
not included in our assessment of methodological quality.
Follow -up
We extracted the number and reasons for all losses to follow-up to
assess the risk of attrition bias.
Statistical analyses
The analyses were performed in RevMan Analysis 1.0 (RevMan
2003) and Stata version 6.0 for Windows. The number of events
and number of patients in all intervention arms were used to
calculate relative risks (RR) with 95% confidence intervals (CI).
Risk differences with 95% CI were also analysed and tabulated
for outcome differences. Continuous outcomes were presented as
weighted mean differences (WMD) with 95% CI. Because we ex-
pected considerable homogeneity, data were combined in fixed-ef-
fect meta-analyses. Random-effects meta-analyses were performed
as sensitivity analyses, but were only to be reported if the results
differ significantly from the fixed-effect models. Intention-to-treat
analyses including all patients irrespective of compliance or follow-
up was performed. Carry forward of the last observed response was
used for patients withmissing data. For the primary outcomemea-
sure, evidence of publication bias and other biases was evaluated
in regression analyses of funnel plot asymmetry. Sources of hetero-
geneity were evaluated through sensitivity, subgroup, and meta-
regression analyses. The analyses included the extracted patient,
intervention, and trial characteristics listed above as explanatory
variables. VMcAlister performed all meta-analyses in RevMan. LL
Gluud performed additional blinded statistical analyses includ-
ing meta-regression and regression analyses of funnel plot asym-
metry. The following subgroup analyses were carried out: pae-
diatric recipients; patients infected with hepatitis C virus at the
time of transplantation; trials using oil-based cyclosporine; trials
where cyclosporine was combined with azathioprine; trials where
tacrolimus and cyclosporine are combined with mycophenolate
mofetil or sirolimus. Sensitivity analyses that combine outcomes
from trials where follow-up data for one year were not available,
even after correspondence with the principle investigator, were
performed using a time point closest to one year (either less or
more) that was available.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Searches performed on August 30, 2005 resulted in 717 hits. This
yielded 114 reports when duplicates were removed. After initial
review, 20 randomised trials were identified of which four were ex-
cluded on further examination because they were a review of other
studies (Arnold 1995), a sub-analysis of another study (Loinaz
2001), or designed for other purposes, usually regarding perioper-
ative care, without any of the outcomes being studied for inclusion
in this systematic review (Ericzon 1997; Trull 2002). Data at one
year after liver transplantation were available in all the remaining
16 trials, except for two in which data were only available at three
months (Timmermann 2002) and at six months(Stegall 1997).
In one trial data were available at one year with the exception of
graft loss, which was only available at six months (Grazi 2004). Af-
ter contacting principal investigators and sponsoring pharmaceu-
tical companies supplementary information was supplied regard-
ing eight reports (Fung 1991; Fisher 1998; Klupp 1999; Loinaz
2001; Muehlbacher 2001; Therapondos 2002; Greig 2003; Grazi
2004).
Included trials
The 16 included trials allocated 3813 participants of whom 1899
were randomised to tacrolimus and 1914 to cyclosporin. Seven
of the trials were conducted at single centre sites (Fung 1991;
Stegall 1997; Fisher 1998; Zervos 1998; Klupp 1999; Rolles 1999;
Therapondos 2002), while the remaining nine trials were multi-
centred. In all, the trials involved 59 liver transplantation centres in
18 countries.Most of the randomised trials restricted enrolment to
adults, but one included children (U. S. Study 1994) and one was
restricted to children (Kelly 2004). Hepatitis C virus (HCV) cir-
rhosis was the commonest indication for transplantation in studies
after 1994; two randomised trials confined entry to patients with
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hepatitis C virus (HCV) (Zervos 1998; Martin 2004); only one
other trial identified the outcome in patients with HCV (Grazi
2004). The three earliest trials with 1157 participants compared
tacrolimus with the original oil based formulation of cyclosporin
(Sandimmun®) (Fung 1991; European Study 1994; U. S. Study
1994)whereas the other 15 trials with 1656 participants compared
tacrolimus with the microemulsion formulation (Neoral®). Con-
comitant immunosuppression given to all patients (both study
groups, all participating centres) included corticosteroids (all trials
except Rolles 1999); azathioprine (O’Grady 2002; Therapondos
2002; Greig 2003; Martin 2004), and mycophenolate mofetil (
Stegall 1997; Fisher 1998; Klupp 1999). In one multi-centred
trial, azathioprine was given only in some centres but to both study
groups (Grazi 2004). In five trials, azathioprine was given only to
cyclosporin treated patients according to local practice (European
Study 1994; U. S. Study 1994;Muehlbacher 2001; Timmermann
2002; Kelly 2004). All of the trials used trough level monitoring
to guide cyclosporin and tacrolimus dosing except one trial (Grazi
2004), which used the two hour post-dose level to guide the dose
of cyclosporin.
Risk of bias in included studies
Allocation concealment was adequate in most trials. The method
of allocation concealment was not specified in three trials (Stegall
1997; Zervos 1998; Rolles 1999). All of the trials were open la-
belled because of the need for therapeutic drugmonitoring. Inten-
tion-to-treat analysis was available in all the trials. Follow-up data
were complete for patient and graft survival (primary outcome)
and for rejection, but reduced in all other categories. In one trial
graft survival was only reported at six months, but all other data
were available at 12 months after transplantation (Grazi 2004).
Effects of interventions
The primary outcome favoured tacrolimus. Mortality at one year
was reduced by 15% in the tacrolimus patients (comparison 01.01:
RR 0.85, 95% CI 0.73 to 0.99). Graft survival was reported in
15 trials favouring tacrolimus with 22% less grafts lost (compari-
son 01.02: RR 0.78, 95% CI 0.68 to 0.89). Rejection and steroid
resistant rejection were reduced by 18% and 43%, respectively,
in the tacrolimus treated recipients (comparison 01.03: RR 0.82,
95% CI 0.77 to 0.88; comparison 01.04: RR 0.57, 95% CI 0.46
to 0.71). These results are from intention-to-treat analyses. Sub-
stantially more patients discontinued cyclosporin than tacrolimus
(comparison 01.10: RR 0.65, 95%CI 0.57 to 0.74). However, the
rate of new-onset diabetes was increased by 27% in the tacrolimus-
treated patients (comparison 01.08: RR 1.27, 95% CI 1.12 to
1.44).
No differences were seen in the rates of chronic renal failure re-
quiring dialysis ((comparison 01.05: RR 1.55, 95% CI 0.64 to
3.78) or of lymphoproliferative disorder after liver transplantation
(comparison 01.09: RR 1.01, 95% CI 0.36 to 2.86). Differences
in the serum creatinine at one year favouring tacrolimus were not
statistically significant, but data were available from only two tri-
als with a total of 672 patients (comparison 01.07: RR, -2.67
mmol/L, 95% CI -9.55 to 4.22). Insufficient data were reported
regarding other adverse events for systematic analysis, but the data
are included in the characteristics of included trials table.
The number of deaths was 254 in the tacrolimus group (1899
patients) and 302 in the cyclosporin group (1914 patients). The
actual number of patients and events are presented in Table 1 with
the absolute risk differences and 95% CI. Treating 100 recipients
with tacrolimus instead of cyclosporin would avoid rejection and
steroid-resistant rejection in nine and seven patients, respectively,
and graft loss and death in five and two patients, respectively,
but four additional patients would develop diabetes after liver
transplantation.
Table 1. Number of patients (N), events (n), risk difference, 95% confidence interval CI
Event Tacrolimus n/N
(%)
Cyclosporin n/N
(%)
risk difference 95% CI minimum 95% CI maximum
Death 254 / 1899 (13.4%) 302 / 1914 (15.8%) -2% 0% -5%
Graft loss 281 / 1654 (17.0%) 365 / 1664 (21.9%) -5% -2% -8%
Acute rejection 720 / 1865 (38.6%) 885 / 1881 (47.0%) -9% -6% -12%
Steroid-resistant re-
jection
110 / 1193 (9.2%) 205 / 1246 (16.5%) -7% -4% -9%
Drug discontinua-
tion
222 / 1573 (14.1%) 392 / 1583 (24.8%) -11% -8% -13%
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Table 1. Number of patients (N), events (n), risk difference, 95% confidence interval CI (Continued)
Diabetes 306 / 1503 (20.4%) 242 / 1520 (15.9%) 4% 2% 7%
Regression asymmetry tests showed no significant evidence
of publication bias or other biases (P = 0.33). In meta-regression
analyses the treatment effect was not significantly associated with
the allocation sequence generation (regression coefficient -0.022,
95% CI -0.57 to 0.52) or allocation concealment (regression coef-
ficient -0.17, 95% CI -0.48 to 0.15). Identical results for the pri-
mary outcome were found whether fixed-effect or random-effects
meta-analyses were used because the studies lack heterogeneity, I
2 = 0%. Random-effects meta-analyses did not change the other
outcomes.
Stratified analyses showed that the heterogeneity of the trials and
the outcomes were not altered by inclusion of the following sub-
groups: (1) oil-based cyclosporin (comparison 02) (Fung 1991;
European Study 1994; U. S. Study 1994); (2) trials with chil-
dren (comparison 03) (U. S. Study 1994; Kelly 2004), and (3)
trials not reporting 12 month data (comparison 04) (Stegall 1997;
Timmermann 2002; Grazi 2004). Separate analyses of these sub-
groups showed similar results to the rest of the trials except that
some subgroups were of insufficient size for the differences to be
statistically significant. Stratified analysis of trials confined to pa-
tients with HCV (Zervos 1998; Martin 2004) did not alter the re-
sult when combined with the other trials, all of which included pa-
tients with HCV and other diagnoses (comparison 05). Stratified
analysis of the different protocols of concomitant immunosup-
pression with azathioprine or mycophenolate mofetil also showed
similar results in each subgroup, but the sample sizes were much
reduced by the stratification (comparison 06). Reporting of actual
doses and levels of drug used was too sparse to permit more de-
tailed analysis, and the results are given in the characteristics table
of each trial. Similarly, other adverse events, which were not re-
ported regularly enough for comparison, are reported in the char-
acteristics table of each trial.
D I S C U S S I O N
Cyclosporin was introduced, without the benefit of clinical trial,
into care of the recipient after liver transplantation. Even at the
time that tacrolimus was developed, considerable hesitancy re-
mained regarding the robustness of liver transplantation to allow
for randomisation. This concern is apparent in a description of the
earliest randomised trial in this review (Fung 1991) and in a discus-
sion of the two registration randomised clinical trials of tacrolimus
(Starzl 1995). In the succeeding decade, a further 13 randomised
clinical trials of tacrolimus versus cyclosporin in liver transplanta-
tion were performed indicating increasing comfort with the proce-
dure. This systematic review shows why this occurred. Outcomes
after liver transplantation are very good. Overall patient and graft
survival rates are 85% and 80%, respectively.
The superiority of tacrolimus over cyclosporin after liver trans-
plantation has to be considered in the context of these excellent
overall results. Calculating the risk difference of each treatment
helps us understand its impact. Treating 100 liver recipients with
tacrolimus instead of cyclosporin would result in two less deaths,
five less graft losses, nine less patients with acute rejection, and
seven less with steroid-resistant rejection, but four more patients
would develop diabetes. The ranges suggested by 95%CI for these
risk differences are included in Table 1.
More heterogeneity between the trials is seen in rejection than
in other outcomes. One source of heterogeneity here may be the
variable rates of rejection observed in each trial. This is probably
due to the evolution of rejection diagnosis over time. Definition
of rejection was standardised within trials, but not between trials.
The rate of diagnosis of rejection appears to be lower inmore recent
trials than in earlier ones, even though the immunosuppressive
protocols are similar. This might be due to improved differential
diagnostic ability and a reduced liver biopsy rate, but these features
are beyond the scope of this review. There was no evidence that
different criteria were applied to recipients of either tacrolimus or
cyclosporin in the trials. Despite the heterogeneity, a consistent
finding in each trial was a clinically and statistically significantly
lower rate of rejection in liver transplant recipients randomised to
tacrolimus.
Relatively few trials excluded adjuvant immunosuppression with
either azathioprine or mycophenolate mofetil. Several trials per-
mitted use of azathioprine in cyclosporin, but not tacrolimus
treated patients at centres where this was the normal practice. One
trial permitted this use of azathioprine at certain centres only if it
were also prescribed to tacrolimus recipients. More recently trials
of concomitant mycophenolate mofetil given to both groups have
been performed. Stratification of the analyses according to the dif-
ferent forms of adjuvant immunosuppression reduced the sample
size so that conclusions cannot be drawn with respect to mortality,
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but most of the other comparisons did not show any impact of
adjuvant immunosuppression on the differences reported above
between cyclosporin and tacrolimus.
The outcomes studied are reported on the basis of intention to
treat. Cyclosporin discontinuation does not ameliorate the dis-
advantage associated with that group. The benefit of switching
from cyclosporin to tacrolimus or vice versa cannot be evaluated
from these trials. This review looked at outcomes one year after
transplantation. The impact of diabetes may not be manifest for
many years. The risk of post-transplant lymphoproliferative dis-
order persists beyond one year, so that outcomes for the groups
with respect to that comparison may change. Similarly the risk
of calcineurin inhibitor related nephrotoxicity may increase with
time. The results of this review must be considered in the context
of possible long-term outcomes.
The involvement of the majority of transplant centres through-
out the world in the randomised trials reviewed combined with
the lack of heterogeneity of the trials support the veracity of this
review. Very similar results with respect to graft survival, rejec-
tion, and diabetes were achieved by a recent Cochrane review of
tacrolimus and cyclosporin in kidney transplantation (Webster
2005). Both cyclosporin and tacrolimus are immunosuppressive
because they inhibit calcineurin phosphatase in lymphocytes. In-
hibition of the same pathway in the beta-cells of the pancreas re-
duces insulin production. The superior effect of tacrolimus in the
prevention of rejection was accompanied by an increase in the rate
of diabetes in this review and in the kidney transplantation meta-
analysis (Webster 2005). The difference between cyclosporin and
tacrolimus may, therefore, be related to the potency of calcineurin
phosphatase inhibition. Insufficient data regarding exposure to cy-
closporin or tacrolimus were reported to know if the outcomes
would merge with particular dosing protocols. The higher rate of
cyclosporin discontinuation seen consistently throughout the re-
views suggests that clinicians find it more difficult to achieve the
balance between efficacy and unwanted effects with that medi-
cation than with tacrolimus. Differences between cyclosporin or
tacrolimus in pharmacokinetic profiles or in secondary adverse
events may account for this difficulty.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Tacrolimus is superior to cyclosporin in patients after liver trans-
plantation. Liver transplant recipients on tacrolimus need careful
monitoring for the development of diabetes.
Implications for research
More research with cyclosporin and tacrolimus is required to dis-
associate the unwanted effects of calcineurin inhibition from the
intended immunosuppressive effect. These investigations may ex-
ploit the different pharmacokinetic profiles, different drug inter-
actions, and different adverse effect profiles of cyclosporin and
tacrolimus to maintain maximum patient and graft survival with
minimum adverse events.
A C K N OW L E D G E M E N T S
Our thanks to SarahKlingenberg, the Trials SearchCoordinator of
The Cochrane Hepato-Biliary Group for suggesting search strate-
gies and performing electronic searches in the Controlled Trials
Register of The Cochrane Library, to Dimitrinka Nikolova for
excellent co-ordination, and to Christian Gluud for advice and
support. We are grateful to the editor and reviewers for their sug-
gestions at each stage of the review.
R E F E R E N C E S
References to studies included in this review
European Study 1994 {published data only}
European FK506 Multicentre Liver Study Group. Randomised
trial comparing tacrolimus (FK506) and cyclosporin in prevention
of liver allograft rejection. Lancet 1994;344:423–8. [MEDLINE:
7520105]
Fisher 1998 {published and unpublished data}
∗ Fisher RA, Ham JM, Marcos A, Shiffman ML, Luketic VA,
Kimball PM, et al.A prospective randomized trial of mycophenolate
mofetil with neoral or tacrolimus after orthotopic transplantation.
Transplantation 1998;66(12):1616–21. [MEDLINE: 9884248]
Fisher RA, Stone JJ, Wolfe LG, Rodgers CM, Anderson ML,
Sterling RK, et al.Four-year follow-up of a prospective randomized
trial of mycophenolate mofetil with cyclosporine microemulsion or
tacrolimus following liver transplantation. Clinical Transplantation
2004;18(4):436–72. [MEDLINE: 15233827]
Fung 1991 {published and unpublished data}
∗ Fung J, Abu-Elmagd K, Jain A, Gordon R, Tzakis A, Todo S, et
al.A randomized trial of primary liver transplantation under
immunosuppression with FK 506 vs cyclosporine. Transplantation
Proceedings 1991;23(6):2977–83. [MEDLINE: 172133]
Fung JJ, Eliasziw M, Todo S, Jain A, Demetris AJ, McMichael JP, et
al.The Pittsburgh randomized trial of tacrolimus compared to
cyclosporine for hepatic transplantation. Journal of the American
College of Surgeons 1996;183(2):117–25. [MEDLINE: 8696542]
Grazi 2004 {published and unpublished data}
∗ Grazi GL, Levy G, Wu Y, Marotta P, Boillot O, Sanjuan F, et
al.12-month follow-up data from a randomized multicentre,
prospective study of cyclosporine C2 monitoring versus tacrolimus
7Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
in liver transplantation (LIS2T). American Journal of
Transplantation 2004;4(Suppl 8):268.
Levy G, Villamil F, Samuel D, Sanjuan F, Grazi GL, Wu Y, et
al.Results of LIS2T, a multicenter, randomized study comparing
cyclosporine microemulsion with C2 monitoring and tacrolimus
with C0 monitoring in de novo liver transplantation.
Transplantation 2004;77(11):1632–8. [MEDLINE: 15201658]
Greig 2003 {published and unpublished data}
Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, et
al.Early steroid withdrawal after liver transplantation: the Canadian
tacrolimus versus microemulsion cyclosporin A trial. 1-year follow-
up. Liver Transplantation 2003;9(6):587–95. [MEDLINE:
12783400]
Kelly 2004 {published data only}
Kelly D, Jara P, Rodeck B, Lykavieris P, Burdelski M, Becker M, et
al.Tacrolimus and steroids versus ciclosporin microemulsion,
steroids, and azathioprine in children undergoing liver
transplantation: randomised European multicentre trial. Lancet
2004;364:1054–61. [MEDLINE: 15380964]
Klupp 1999 {published and unpublished data}
Klupp J, Glanemann M, Bechstein WO, Platz KP, Langrehr JM,
Keck H, et al.Mycophenolate mofetil in combination with
tacrolimus versus neoral after liver transplantation. Transplantation
Proceedings 1999;31:1113–4. [MEDLINE: 10083497]
Martin 2004 {published data only}
Martin P, Busuttil RW, Goldstein RM, Crippin JS, Klintmalm GB,
Fitzsimmons WE, et al.Impact of tacrolimus versus cyclosporine in
hepatitis C virus-infected liver transplant recipients on recurrent
hepatitis: a prospective randomized trial. Liver Transplantation
2004;10(10):1258–62. [MEDLINE: 15376310]
Muehlbacher 2001 {published and unpublished data}
∗ Muehlbacher FF, for the European Liver Transplantation
Tacrolimus vs Cyclosporin Microemulsion Study Group.
Tacrolimus versus cyclosporin microemulsion in liver
transplantation: results of one-year follow-up. 10th ESOT & 12th
ETCO Congress 2001, October 6-11, 2001, Lisboa, Portugal.
2001.
Muhlbacher F, European Liver Transplantation Tacrolimus vs
Cyclosporin Microemulsion Study Group. Tacrolimus versus
cyclosporin microemulsion in liver transplantation: results of a 3-
month study. Transplantation Proceedings 2001;33(1-2):1339–40.
[MEDLINE: 11267317]
O’Grady 2002 {published data only}
O’Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A, The
UK and Republic of Ireland Liver Transplant Study Group.
Tacrolimus versus microemulsified ciclosporin in liver
transplantation: the TMC randomised controlled trial. Lancet
2002;360:1119–25. [MEDLINE: 12387959]
Rolles 1999 {published data only}
Rolles K, Davidson BR, Burroughs AK. A pilot study of
immunosuppressive monotherapy in liver transplantation:
tacrolimus versus microemulsified cyclosporin. Transplantation
1999;68(8):1195–209. [MEDLINE: 10551650]
Stegall 1997 {published data only}
Stegall M, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R,
et al.Prednisone withdrawal 14 days after liver transplantation with
mycophenolate: a prospective trial of cyclosporine and tacrolimus.
Transplantation 1997;64(12):1755–60. [MEDLINE: 9422416]
Therapondos 2002 {published and unpublished data}
Therapondos G, Flapan AD, Dollinger MM, Garden OJ, Plevris
JN, Hayes PC. Cardiac function after orthotopic liver
transplantation and the effects of immunosuppression: a
prospective randomized trial comparing cyclosporin (Neoral) and
tacrolimus. Liver Transplantation 2002;8(8):690–700.
[MEDLINE: 12149762]
Timmermann 2002 {published data only}
Timmermann W, Erhard J, Lange R, Reck T, Kockerling F, Muller
A, et al.A randomised trial comparing the efficacy and safety of
tacrolimus with microemulsified cyclosporine after liver
transplantation. Transplantation Proceedings 2002;34(5):1516–8.
[MEDLINE: 12176463]
U. S. Study 1994 {published data only}
The US Multicentre FK506 Study Group. A comparison of
tacrolimus (FK 506) and cyclosporine for immunosuppression in
liver transplantation. New England Journal of Medicine 1994;331
(17):1110–5. [MEDLINE: 7523946]
Zervos 1998 {published and unpublished data}
Zervos XA, Weppler D, Fragulidis GP, Torres MB, Nery JR, Khan
MF, et al.Comparison of tacrolimus with microemulsion
cyclosporine as primary immunosuppression in hepatitis C patients
after liver transplantation. Transplantation 1998;65(8):1044–6.
[MEDLINE: 9583863]
References to studies excluded from this review
Arnold 1995 {published data only}
Arnold JC, Theilmann L. Comparison between tacrolimus (FK
506) and cyclosporin in immunosuppressive therapy after liver
transplantation [Vergleich zwischen Tacrolimus (FK 506) und
Cyclosporin in der immunosuppressiven Therapie nach
Lebertransplantation]. Zeitschrift fur Gastroenterologie 1995;33(10):
624–5. [MEDLINE: 7502559]
Ericzon 1997 {published data only}
Ericzon B, Eusufzai S, Soderdahl G, Duraj F, Einarsson K, Angelin
B. Secretion and composition of bile after human liver
transplantation. Transplantation 1997;63(1):74–80. [MEDLINE:
9000664]
Loinaz 2001 {published and unpublished data}
Loinaz C, Marin LM, Gonzalez-Pinto I, Gomez R, Jimenez C,
Moreno E. A single-centre experience with cyclosporine
microemulsion versus tacrolimus in 100 randomized liver
transplant recipients: midterm efficacy and safety. Transplantation
Proceedings 2001;33:3439–41. [MEDLINE: 11750472]
Trull 2002 {published data only}
Trull A, Hughes V, Cooper D, Wilkins M, Gimson A, Friend P, et
al.Influence of albumin supplementation on tacrolimus and
cyclosporine therapy early after liver transplantation. Liver
Transplantation 2002;8(3):224–32. [MEDLINE: 11910567]
Additional references
8Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Higgins 2005
Higgins JPT, Green S, editors. Cochrane Handbook for Systematic
Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane
Library, Issue 3, 2005. Chichester, UK: John Wiley & Sons, Ltd.
Kjaergard 2001
Kjaergard LL, Villumsen J, Gluud C. Reported methodologic
quality and discrepancies between large and small randomized trials
in meta-analyses. Annals of Internal Medicine 2001;135(11):982–9.
[MEDLINE: 11730399]
Knoll 1999
Knoll GA, Bell RC. Tacrolimus versus cyclosporin for
immunosuppression in renal transplantation: meta-analysis of
randomised trials. BMJ (Clinical Research Ed.) 1999;318(7191):
1104–7. [MEDLINE: 10213717]
RevMan 2003
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration. Review Manager (RevMan). 4.2 for Windows.
Copenhagen: The Nordic Cochrane Centre, The Cochrane
Collaboration, 2003.
Royle 2003
Royle P, Milne R. Literature searching for randomized controlled
trials used in Cochrane reviews: rapid versus exhaustive searches.
International Journal of Technology Assessment in Health Care 2003;
19(4):591–603.
Siekierka 1992
Siekierka JJ, Sigal NH. FK-506 and cyclosporin A:
immunosuppressive mechanism of action and beyond. Current
Opinion in Immunology 1992;4(5):548–52. [MEDLINE:
1384551]
Starzl 1985
Starzl TE, Iwatsuki S, Shaw BW Jr, Gordon RD, Esquivel CO.
Immunosuppression and other nonsurgical factors in the improved
results of liver transplantation. Seminars in Liver Disease 1985;5(4):
334–43. [MEDLINE: 3909427]
Starzl 1995
Starzl TE, Donner A, Eliasziw M, Stitt L, Meier P, Fung JJ, et
al.Randomised trialomania?The multicentre liver transplant trials
of tacrolimus. Lancet 1995;346(8986):1346–50. [MEDLINE:
7475777]
Webster 2005
Webster A, Woodroffe R, Taylor R, Chapman J, Craig J.
Tacrolimus versus cyclosporin as primary immunosuppression for
kidney transplant recipients. The Cochrane Database of Systematic
Reviews 2005, Issue 4. Art. No.: CD003961. DOI: 10.1002/
14651858.CD003961.pub2.
∗ Indicates the major publication for the study
9Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
European Study 1994
Methods Generation of the allocation sequence: adequate. Randomly assigned to treatment within centres in blocks
of 4, each block containing an equal number allocated to the 2 treatment groups; stratified for the presence
of fulminant hepatic failure.
Allocation concealment: adequate. Third party allocation.
Blinding: not performed.
Follow-up: adequate.
Participants Country: Eight centres in four European countries.
Language: English.
Inclusion criteria: Male and female patients, aged 18 to 70, undergoing primary isolated liver transplan-
tation.
Exclusion criteria / diagnoses: vasculitis, primary liver cancer with metastases, HIV, treatment with an
investigational agent.
Allocation: tacrolimus n = 264; cyclosporin n = 265.
Interventions Tacrolimus protocol:
- 0.075 mg/kg IV over 4 hours q 12 h for 3 days then conversion to oral at 0.30 mg/kg/d
- during the study changes to the tacrolimus regimen resulted in a lower daily dose
- all tacrolimus patients also received IV methylprednisolone at 10 mg/kg intra-op or post-op (single dose)
followed by 20 mg/d prednisolone or equivalent methylprednisolone if patient unable to take oral
- steroids tapered and withdrawal was acceptable.
Cyclosporin protocol:
- cyclosporin formulation: oil-based
- centre dependent - 1 to 6 mg/kg IV or 8 to 15 mg/kg oral
- all cyclosporin patients also received azathioprine from 1 to 3 mg/kg, steroids from 0.5 to 2.0 mg/kg
- in three cantres the cyclosporin patients received ATG 5 mg/kg/d for 1 week .
Concomitant immunosuppression: steroids to all patients; antithymocyte globulin to both groups at 3
centres; azathioprine to cyclosporin recipients according to local practice.
Outcomes - patient survival
- graft survival
- acute rejection
- refractory rejection
- chronic rejection
- insulin dependent DM
- creatinine
- infection
- withdrawal
- impaired renal function
- neurologic complications
- hirsutism
Notes Follow-up: 12 months
Other adverse events:
tremor - tacrolimus (127/264); cyclosporin (85/265)
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European Study 1994 (Continued)
paraesthesia - tacrolimus (45/264), cyclosporin (44/265)
infection - tacrolimus (99/264); cyclosporin (107/265)
cytomegalovirus - tacrolimus (41/264); cyclosporin (58/265)
pneumonia - tacrolimus (43/264); cyclosporin (56/265).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Fisher 1998
Methods Generation of the allocation sequence: adequate. Random numbers.
Allocation concealment: adequate. Third party allocation.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: USA.
Language: English.
Inclusion criteria: adult patients, male and female, undergoing orthotopic liver transplantation.
Exclusion criteria: not specified.
Allocation: tacrolimus n = 49; cyclosporin n = 50.
Interventions Tacrolimus protocol:
- 0.15 mg/kg/d orally twice per day started on day 2 to maintain blood levels of 10 to 15 ng/ml for 2
months and 5 to 10 ng/ml thereafter.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- cyclosporin 8 to 10 mg/kg/d orally twice per day starting on day 2 to maintain blood level of 300 to
400 ng/ml for 2 months and 200 to 300 ng/ml thereafter:
Concomitant immunosuppression: steroids all patients; MMF all patients.
- all patients received 1.5 g of MMF orally 4-6 hrs prior to transplantation; during 1st week MMF at 3
g/d if blood loss < 10 U and 2 g/d if >= 10 U; reduced to 2 g/d after 7 days and 1 g/d by 6 months (
decreased by 50% or discontinued of WBC < 4)
- prednisone was tapered to 20 mg/d by day 18, 7.5 mg/d by 3 months, 5 mg/d by 6 months
- patients received PGE1 as a continuous central venous infusion over 5 to 7 days beginning at 10 ug/hr
(dose dependant on SBP, plts, diarrhoea). PGE1 was stopped or restarted at a lower dose if SBP < 100
mmHg, plt < 60,000 or incapacitating diarrhoea
- CMV treatment and prophylaxis regimens (details in article)
- HBV treatment of positive patients.
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- ALT, AST, ALP, total bilirubin
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Fisher 1998 (Continued)
- serum creatinine
- haemoglobin, WBC
- hypertension, hypercholesterolaemia, DM, BMI
- conversion
- readmission
Notes Follow-up: initial report 6 months, later report at 4 years.
Correspondence with principle investigator: May 2004 regarding 12 month outcomes
Other adverse events (at 6 months):
Infections - tacrolimus (24/49); cyclosporin (30/50)
CMV - tacrolimus (3/49); cyclosporin (9/50).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Fung 1991
Methods Generationof the allocation sequence: adequate, computer program implemented the block randomisation
technique.
Allocation concealment: adequate, sealed envelope each containing a single treatment assignment.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: USA.
Language: English.
Inclusion criteria: All male and female patients, from 16 to 60 years, undergoing primary isolated liver
transplantation.
Exclusion criteria / diagnoses: hepatitis B virus; cancer; infection; advanced renal failure; coma; previous
hepatic surgery; pregnancy or nursing.
Allocation: tacrolimus n = 41; cyclosporin n = 40.
Interventions Tacrolimus protocol:
- 0.1 mg/kg IV over 24 hours beginning 4 hours after the revascularization of the new liver and continued
daily until they were able to take po meds, then 0.15 mg/kg po q 12 h
- maintain trough levels from 1.0 to 5.0 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: oil-based
- 4 mg/kg IV over 24 hours, beginning 4 hours after revascularization until patient was able to take po
meds, then 8 mg/kg po q 12 h to maintain trough level of 800 to 1500 ng/ml x 2 months then decrease
dose to maintain trough of 600 to 800 ng/ml thereafter:
Concomitant immunosuppression: steroids all patients.
-in both groups, single intra-op 1 g methylprednisolone followed by a daily dose of 20 mg/d until oral
dose was started
- a dose of 10 mg/d was allowed at 2 weeks if no evidence of rejection
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Fung 1991 (Continued)
- a further reduction to 5 mg/d was allowed at the end of 1 month if no evidence of rejection
- patients were taken off steroids if there was no evidence of rejection.
Outcomes - patient survival
- graft survival
- graft rejection
- steroid resistant rejection
- conversion
- serum creatinine
- dialysis
- CMV, TB, HCV, HBV, HSV infection
- PTLD.
Notes Follow-up: 12 months.
Correspondence with principle investigator: May 2004 regarding 12 month outcomes.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Grazi 2004
Methods Generation of the allocation sequence: adequate, stratified according to hepatitis C virus.
Allocation concealment: adequate, central assignment.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Argentina, Australia, Austria, Belgium, Brazil, Canada, France, Germany, Italy, Japan, New
Zealand, Norway, Spain, Sweden, Switzerland, United Kingdom, USA.
Language: English.
Inclusion criteria: All male and female patients, 18 to 75 years, undergoing primary isolated liver trans-
plantation.
Exclusion criteria / diagnoses: ABO blood group incompatibility, non-heart-beating donor, cancer, HIV,
unstable fulminant liver failure.
Allocation: cyclosporin n = 250; tacrolimus n = 245.
Interventions Tacrolimus protocol:
- started within 24 hours of transplant
- from 0.1 to 0.15 mg/kg/d in 2 divided doses po
- after first dose adjusted in target range of 5 to 15 ng/ml at month 3 and from 5 to 12 ng/ml to month 6.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- started within 24 hours of transplant
- from 10 to 15 mg/kg/d in 1 divided doses po
- after first dose adjusted to achieve target range of 0.8 to 1.2 ug/ml to month 3 and from 0.7 to 0.9 ug/ml
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Grazi 2004 (Continued)
to month 6.
Concomitant immunosuppression: steroids all patients; azathioprine according to local centre practice
but had to be the same for both arms at that centre.
Tacrolimus actual:
- approximated from figure 1
- dose at 1 month 8.29 mg/kg/d (SD 4)
- dose at 3 months 5.14 mg/kg/d (SD 2.14)
- dose at 6 months 4.57 mg/kg/d (SD 1.71)
- level at 1 month 1157 ng/ml (SD 371)
- level at 3 months 942.9 ng/ml (SD 286)
- level at 6 months 771.4 ng/ml (SD 343).
Cyclosporin actual:
- approximated from figure 1
- dose at 1 month 0.13 mg/kg/d (SD 0.066)
- dose at 3 months 0.12 mg/kg/d (SD 0.066)
- dose at 6 months 0.109 mg/kg/d (SD 0.057)
- level at 1 month 11.14 ng/ml (SD 4)
- level at 3 months 9.7 ng/ml (SD 3.7)
- level at 6 months 9.5 ng/ml (SD 3.4)
- can use IV dose of cyclosporin or tacrolimus
- all received steroids, 1 g methylprednisolone intra-op, day 1 200 mg/d or 3 mg/kg/d of prednisone,
tapered to a level from 10 to 20 mg by day 7 to end of first month. During second and third month dose
was 7.5 to 15 mg/d. End of third month onward 5 to 10 mg/d
- withdrawal of steroids not permitted during first 6 months
- for HVC patients steroids adjusted to local practice
- no MMF or induction therapy
- for patient given antithymocyte globulin, antilymphocyte globulin or OKT3 for rejection, cyclosporin
or tacrolimus could be stopped for up to 14 consecutive days
- dose of azathioprine according to local practice, but had to be the same for all patients in both arms
within each centre.
Outcomes - patient survival
- graft survival
- acute rejection
- serum creatinine
- malignancy
- diabetes
- hyperlipidaemia
- hypertension.
Notes Follow-up: 6 months in first published report; 12 month data reported by abstract.
Correspondence with sponsor regarding 12 month outcomes, August 2004.
Other adverse events:
Event - tacrolimus (n = 254); cyclosporin (250)
Any infection - 148; 158
Neoplasm - 3; 5
Hypertension - 89; 105
Diarrhoea - 70; 34
Convulsions - 15; 14
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Headache - 45; 42
Psychiatric disorders - 121; 109
Hirsutism - 0; 10
Alopecia - 4; 5
Gingival hyperplasia - 0; 5
Pruritus - 19; 13.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Greig 2003
Methods Generation of the allocation sequence: adequate, stratified by centre.
Allocation concealment: adequate, central assignment.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Canada, multiple centres.
Language: English.
Inclusion criteria: All male and female patients, over 16 years, undergoing primary isolated liver trans-
plantation.
Exclusion criteria / diagnoses: ABO blood group incompatibility, advanced renal failure, cancer, acute
pancreatitis, life expectancy less than 2 weeks.
Allocation: tacrolimus n = 71; cyclosporin n = 72.
Interventions Tacrolimus protocol:
- from 0.1 to 0.15 mg/kg/d divided twice daily NG/po to maintain target trough of 10 to 20 ng/ml during
1st month and from 5 to 15 ng/ml thereafter
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- from 10 to 15 mg/kg/d divided twice daily NG/po to maintain target trough of 300 to 400 ng/ml days
1 to 14, from 250 to 350 ng/ml days 15 to 28, from 200 to 300 ng/ml days 29 to 90 and from 100-250
ng/ml thereafter:
Concomitant immunosuppression: steroids all patients; azathioprine all patients.
Tacrolimus actual:
- approximated from Figure 2
- dose at 1 month 14 mg (SD 6.5)
- dose at 3 months 11 mg (SD 6.0)
- dose at 6 months 9 mg (SD 5.5)
- dose at 12 months 7 mg (SD 5.0)
- trough at 1 month 12.5 ng.ml
- trough at 3 months 11.75 ng/ml
- trough at 6 months 11.75 mg/ml
- trough at 12 months 10 ng/ml.
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Greig 2003 (Continued)
Cyclosporin actual:
- approximated from Figure 2
- dose at 1 month 517 mg (SD 150)
- dose at 3 months 367 mg (SD 133)
- dose at 6 months 300 mg (SD 83)
- dose at 12 months 267 (SD 83)
- trough at 1 month 320 ng/ml
- trough at 3 months 245 ng/ml
- trough at 6 months 230 ng/ml
- trough at 12 months 200 ng/ml
- all pts. received methylprednisolone or prednisone 1.0 mg/kg/d on day 1, 0.8 mg/kg/d on day 2, 0.6
mg/kg/d on day 3, 0.4 mg/kg/d on day 4, 0.3 mg/kg/d (usually 20 mg/d) thereafter during month 1; 0.2
mg/kg/d (usually 15 mg/d) during month 2 and 0.15 mg/kg/d (usually 10 mg/d) during month 3
- all pts. received azathioprine 1 mg/kg/d (usually 50, 75 or 100 mg/d) NG/po
- IV tacrolimus (0.025 mg/kg/d) or cyclosporin A (from 1 to 2 mg/kg/d) was used after the 1st 48 hours
only if adequate trough levels could not be reached with the enterally administered drug.
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- steroid withdrawal
- dialysis
- diabetes
- creatinine
- PTLD
- coma, seizures, confusion, delirium, hallucinations, psychosis, depression, anxiety/nervousness, insom-
nia, somnolence, tremor, headache
- viral, bacterial and fungal infection.
Notes Follow-up: 12 months.
Correspondence with sponsor: June 2004 regarding 12 month outcomes.
Other adverse events (only % reported):
Events - tacrolimus; cyclosporin
Coma - 0; 7%
Seizures - 3%; 3%
Confusion - 23%; 30%
Delirium - 4%; 7%
Hallucinations - 14%; 13%
Psychosis - 1%; 1%
Depression - 24%; 18%
Anxiety - 63%; 48%
Insomnia - 66%; 46%
Somnolence - 10%; 13%
Tremor - 63%; 57%
Headache - 75%; 64%
Viral infections - 61%; 49%
Bacterial infections - 76%; 69%
Fungal infections - 24%; 25%.
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Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Kelly 2004
Methods Generation of the allocation sequence: adequate, stratified by age (< or => 3 years), type of donation, and
treatment centre.
Allocation concealment: adequate, central assignment.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Europe, multiple centres.
Language: English.
Inclusion criteria: All male and female patients, 16 years or younger, undergoing primary isolated liver
transplantation.
Exclusion criteria / diagnoses: ABO blood group incompatibility, infections, HIV, cancer or history of
cancer, history of sensitivity to test agents.
Allocation: tacrolimus n = 91; cyclosporin n = 90.
Interventions First dose was to be given within 6 hours of transplantation.
Tacrolimus protocol:
- tacrolimus 0.3 mg/kg per day (po,NG, NJ) in two divided doses (doses adjusted to maintain trough
of 10 to 20 mg/L in first 2 weeks, from 10 to 15 mg/L during weeks 3 to 4, from 5 to 15 mg/L during
months 2 to 3 and from 5 to 10 mg/L thereafter)
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- 10 mg/kg/d given in two divided doses (rest of doses adjusted to maintain trough of 250-350 mg/L
within first 2 weeks, from 200-300 mg/L during weeks 3 to 12, from 150-200 mg/L during months 4 to
12 and from 100-150 mg/L thereafter.
Concomitant immunosuppression: steroids all patients; azathioprine to cyclosporin recipients according
to local practice.
Tacrolimus actual:
- mean dose 0.28 mg/kg (SD 0.16) for month 1, 0.18 mg/kg (SD 0.11) months 10 to 12
- mean trough 13.9 mg/L (SD 3.1) month 1, 7.3 mg/L (SD 2.8 for months 10 to12.
Cyclosporin actual:
- mean dose 16.17 mg/kg (SD 9.77) month 1, 8.86 mg/kg (SD 2.96) months 10 to 12
- mean trough 263.4 mg/l (SD 81.5) month 1, 144.0 mg/L (SD 34.9) months 10 to 12
- can obtain approximate 3 and 6 month data from figure 2
- both treatment groups received: IV methyl prednisolone 10 mg/kg intraop and 2 mg/kg per day days 1
to 6
- oral prednisolone was given at daily does of 1 mg/kg at days 7-13, 0.75 mg/kg at days 14 to 20, 0.5
mg/kg at days 21 to 28 and 0.25 mg/kg at months 2 to 3. Thereafter, steroids could be tapered off in
accordance with centres protocol
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Kelly 2004 (Continued)
- patients in cyclosporin group received azathioprine at 1.5 mg/kg/d for the first 3 months, thereafter,
discontinuation was optional.
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- creatinine
Notes Follow-up: 12 months.
Other adverse events:
Event - tacrolimus (n = 91); cyclosporin (n = 90)
Fever - 42; 46
Hypomagnesemia - 36; 26
Hypertension - 35; 42
Abnormal liver function tests - 34, 25
Anaemia - 26; 17
Diarrhoea - 24; 23
Acidosis - 24; 15
Sepsis - 20; 18
Pleural effusion - 20; 17
Ascites - 15; 18
Hirsutism - 1; 25
Gingival hypertrophy - 1; 8
CMV infection - 14; 22
EBV infection - 24; 10.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Klupp 1999
Methods Generation of the allocation sequence: adequate, three-arm trial.
Allocation concealment: adequate, sealed envelope.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Germany, single centre.
Language: English.
Inclusion criteria: Male and female patients undergoing primary isolated liver transplantation.
Exclusion criteria / diagnoses: not specified.
Allocation: cyclosporin/MMF n = 40; tacrolimus/MMF n = 40; tacrolimus n = 40.
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Klupp 1999 (Continued)
Interventions Concomitant immunosuppression: steroids all patients; MMF all patients.
Dosages of tacrolimus, cyclosporin and MMF according to usual protocol of centre, not given in report.
All patients received low dose prednisone.
Cyclosporin formulation: microemulsion
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- OKT3 rescue therapy
- mean bilirubin
- bile production
- bacterial, CMV and fungal infection
- switching from cyclosporin to tacrolimus and vice versa
Notes Follow up: 12 to 26 month outcomes reported. 12 month data supplied by principal investigator in April
2005.
Other adverse events:
Bacterial infections - tacrolimus (14/40); cyclosporin (20/40)
CMV - tacrolimus (13/40); cyclosporin (11/40)
Fungal infections - tacrolimus (8/20); cyclosporin (7/40).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Martin 2004
Methods Generation of the allocation sequence: adequate, stratified by centre.
Allocation concealment: adequate, central randomisation.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: USA, multiple centres.
Language: English.
Inclusion criteria: All male and female patients with hepatitis C virus, 18 years or older, undergoing
primary isolated liver transplantation.
Exclusion criteria / diagnoses: ABO blood group incompatibility, Hepatitis B virus, HIV, cancer, preg-
nancy, lactation.
Allocation: tacrolimus n = 38; cyclosporin n = 41.
Interventions Tacrolimus protocol:
- started 12 hours after transplantation; from 0.1 to 0.15 mg/kg/d adjusted to maintain trough of 5 to 10
ng/mL for 1st 6 months and from 5 to 10 ng/ml for next 6 months.
Cyclosporin protocol:
19Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Martin 2004 (Continued)
- cyclosporin formulation: microemulsion
- started 12 hours after transplantation; from 6 to 10 mg/kg/d adjusted to maintain trough of 200 to 250
ng/ml for first 6 months and 100 to 250 ng/ml for next 6 months:
Concomitant immunosuppression: steroids all patients; azathioprine all patients.
- all patients received periop parenteral steroids which were tapered to 20 mg/d orally on day 6 and
decreased to 5 mg/d at day 90
- all patients received azathioprine - 2 mg/kg/d tapered to 1 mg/kg/d by day 7 and then withdrawn
gradually after 60 days
- no OKT3 was used for rejection.
Outcomes - recurrence of histologically diagnosed hepatitis
- time to hepatitis C virus recurrence
- change in viral load
- graft survival
- patient survival
- biopsy-proven rejection rate.
Notes Follow-up: 12 months.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Muehlbacher 2001
Methods Generation of the allocation sequence: adequate, stratified by centre.
Allocation concealment: adequate, central randomisation.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Europe, multiple centres.
Language: English.
Inclusion criteria: Adult patients, 18 years or older, undergoing primary isolated liver transplantation.
Exclusion criteria / diagnoses: pregnancy, intolerance of test agents, uncontrolled infection, HIV, extra-
hepatic malignancy.
Allocation: tacrolimus n = 310; cyclosporin n = 305.
Interventions Tacrolimus protocol:
- 0.15 mg/kg/d adjusted to achieve trough of 10 to 20 ng/mL for the 1st month and from 5 to 15 ng/mL
thereafter:
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- from 8 to 15 mg/kg adjusted to achieve trough 150-300 ng/mL throughout study.
Concomitant immunosuppression: steroids to all patients; azathioprine to cyclosporin recipients according
to local practice.
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Muehlbacher 2001 (Continued)
Tacrolimus actual:
- mean dose at 1 year 0.07 (+/- 0.045) mg/kg
- mean trough levels at 1 year 9.15 (+/- 3.42) ng/mL.
Cyclosporin actual:
- mean dose at 1 year 3.3 (+/-1.29) mg/kg
- mean trough at 1 year 170( +/- 63) ng/ml
- tapering steroid scheme
- 43% were off steroids in either group at 1 year.
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- hypertension
- need for oral antidiabetic drugs
- use of insulin.
Notes Follow-up: 3 months in first report and 12 months in abstract.
Correspondence with sponsor regarding protocol, 12 month data in June 2004.
Other adverse events (only % reported, only 3 month follow-up):
Event - tacrolimus; cyclosporin
Diarrhoea - 12.9%; 4.9%
Biliary system abnormalities - 5.2%; 9.5%
Hyperuricaemia - 1.3%; 3.9%.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
O’Grady 2002
Methods Generation of the allocation sequence: adequate, stratified and blocked randomised sequences using
computer-generated randomnumbers. Allocationwas stratified for emergency and elective transplantation
within each centre: randomisation for elective treatment had an equal number of blocks of size 6, 8 and
10 and ER treatment had an equal number of blocks of size 4 and 6; blocks were ordered at random.
Allocation concealment: adequate, serially numbered opaque envelopes.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: UK, multiple centres.
Language: English.
Inclusion criteria: All male and female patients, 18 years or older, undergoing primary isolated liver
transplantation.
Exclusion criteria / diagnoses: ABO blood group incompatibility, pregnancy, lactation, contraindication
to test agents.
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O’Grady 2002 (Continued)
Allocation: tacrolimus n = 301; cyclosporin n = 305.
Interventions Preferred assignment within 6 hours of transplantation; initial dose po/NG/NJ within 48 hours of trans-
plant.
Tacrolimus protocol:
- 0.1 mg/kg/d up to a maximum of 10 mg/d to maintain target trough level of 5 to 15 ug/L.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- 10 mg/kg/d divided q 12 h to maintain a target trough level of 200 to 300 ug/ml within the 1st month
and from 150 to 250 ug/ml thereafter
- prednisone in both groups tapering dose starting at 20 mg/day reducing to 7.5 mg/day at 3 months or
equivalent dose of methylprednisolone or hydrocortisone
- azathioprine in both groups at 1 mg/kg/day IV/po.
Outcomes - patient survival
- graft survival
- graft rejection
- diabetes
- renal function
- neurological complications
- body hair abnormalities
- malignant disease
Notes Follow-up: 12 months.
Other adverse events:
Event - tacrolimus (n = 301); cyclosporin (n = 306)
Infection treated - 265; 263
Seizures - 17; 11
Neuropathy (by nerve conduction studies) - 3; 3
Neuropathy (subjective)- 31; 27
Psychosis - 20; 22
Coma - 9; 8
Headaches - 56; 52
Pruritus - 33; 25
Hypertension treated - 56; 70
Hypertrichosis - 9; 25
Alopecia - 20; 7.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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Rolles 1999
Methods Generation of the allocation sequence: not clear.
Allocation concealment: not clear.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: UK, single centre.
Language: English.
Inclusion criteria: Adult patients undergoing primary isolated liver transplantation.
Exclusion criteria / diagnoses: not specified.
Allocation: tacrolimus n = 30; cyclosporin n = 34.
Interventions Tacrolimus protocol:
- 0.05 mg/kg po/NG with first dose within 6 hours of surgery, adjusted to maintain a blood level of 5 to
15 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- 5 mg/kg po/NG with first dose within 6 hours of surgery, adjusted to maintain a blood level from 100
to 300 ng/ml
- no IV formula given.
Concomitant immunosuppression: none.
Tacrolimus actual:
- approximated troughs from figure 3
- trough at 1 month 8.05 ug/ml (SD 0.29)
- trough at 3 months 8.43 ug/ml (SD 0.50)
- trough at 6 months 8.25 ug/ml (SD 0.50)
- trough at 12 months 8.15 ug/ml (SD 0.57).
Cyclosporin actual:
- approximated from figure 3
- trough at 1 month 210 ug/ml (SD 12.5)
- trough at 3 months 175 ug/ml (SD 10)
- trough at 6 months 150 ug/ml (SD 10)
- trough at 12 months 130 ug/ml (SD 15).
Outcomes - patient survival
- graft survival
- acute rejection
Notes Follow-up: 12 months.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
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Stegall 1997
Methods Generation of the allocation sequence: not clear.
Allocation concealment: not clear.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: USA, single centre.
Language: English.
Inclusion criteria: All male and female patients, 18 years or older, undergoing orthotopic cadaver liver
transplantation.
Exclusion criteria / diagnoses: hepatitis B virus.
Allocation: tacrolimus n = 35; cyclosporin n = 36.
Interventions Tacrolimus protocol:
- 6 mg/day po/NG adjusted to maintain a blood level of 10 to 15 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- 600 mg/day po/NG adjusted to maintain a blood level from 300 to 350 ng/ml
- no IV formula given.
Concomitant immunosuppression: steroids all patients; MMF all patients. Prednisone was withdrawn at
2 weeks.
Outcomes - patient survival
- graft survival
- acute rejection.
Notes Follow-up: results only available at 6 months even after correspondence with principle investigator.
Other adverse events:
Hypertension - tacrolimus (3/25); cyclosporin (10/33)
CMV - tacrolimus (2/25); cyclosporin (2/33).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Therapondos 2002
Methods Generation of the allocation sequence: adequate. Computer generated.
Allocation concealment: adequate. Numbered envelopes.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Scotland, single centre.
Language: English.
Inclusion criteria: Adult patients undergoing primary isolated liver transplantation.
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Therapondos 2002 (Continued)
Exclusion criteria / diagnoses: not specified.
Allocation: tacrolimus n = 20; cyclosporin n = 20.
Interventions Tacrolimus protocol:
- oral/NG within 6 hours of transplant
- 0.1 mg/kg, target level from 5 to 15 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- oral/NG within 6 hours of transplant
- 10 mg/kg, target level from 150 to 200 nmol/L
Concomitant immunosuppression: steroids all patients; azathioprine all patients.
Azathioprine 2 mg/kg and prednisolone 20 mg x 4 weeks, reduced by 5 mg per subsequent month.
Outcomes - patient survival
- cardiac events
- withdrawals
- blood pressure
- ECG changes
- echocardiographic data
- brain natriuretic peptide levels
- HRV (?)
- nutritional parameters.
Notes Follow-up: 12 month data provided by principal investigator (April 2005).
Other adverse events:
Cardiac events - tacrolimus (4/20); cyclosporin (4/20).
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Timmermann 2002
Methods Generation of the allocation sequence: adequate. Random numbers.
Allocation concealment: adequate. Third party allocation.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Germany, multiple centres.
Language: English.
Inclusion criteria: Adult patients undergoing primary isolated liver transplantation.
Exclusion criteria / diagnoses: not specified.
Allocation: tacrolimus n = 72; cyclosporin n = 71.
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Timmermann 2002 (Continued)
Interventions Tacrolimus protocol:
- oral/NG within 6 hours of transplant
- 0.1 mg/kg, target level from 5 to 15 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- oral/NG within 6 hours of transplant dosed according to local practice.
Concomitant immunosuppression: steroids and antilymphocyte globulin given to each group according
to local practice; azathioprine given to cyclosporin patients according to local practice.
Outcomes - patient survival
- patient survival
- acute rejection
- diabetes.
Notes Study only maintained for 3 months. Data for later follow up not available, confirmed by sponsor (April
2005).
Other adverse events (only % reported):
Event - tacrolimus; cyclosporin
Infections - 21.5%; 26.1%
CMV - 15.4%; 17.4%
hypertension - 13.8%; 20.3%
tremor - 6.2%; 0.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
U. S. Study 1994
Methods Generation of the allocation sequence: adequate, centrally generated by computer, randomly assigned in
blocks of four.
Allocation concealment: adequate. Numbered envelopes.
Blinding: not performed.
Follow-up: adequate.
Analysis: intention to treat.
Participants Country: Eight centres in four European countries.
Language: English.
Inclusion criteria: Male and female patients, all ages, undergoing primary isolated liver transplantation.
Exclusion criteria / diagnoses: vasculitis, cancer, renal failure, HIV, coma, pregnancy, treatment with
anticoagulants, ABO blood group incompatibility.
Allocation: tacrolimus n = 263; cyclosporin n = 266.
Interventions Tacrolimus protocol:
- initial 0.075 mg/kg in a 4 hours IV infusion every 12 hours until it could be taken orally
- IV was reduced to 0.05 mg/kg over a 12 hour period twice daily after first 48 patients (discovered renal
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U. S. Study 1994 (Continued)
toxicity)
- oral 0.15 mg/kg q 12 h
- patients also received hydrocortisone (1000 mg IV) followed by methylprednisolone (100 mg IV/po,
decreased to 20 mg/d over 5 days)
- treatment with oral prednisone (20 mg po once daily) was initiated in adults, dose was tapered to 5 mg
po od over 3 months
- children - prednisone (10 mg/kg) or equivalent of methylprednisolone IV, decreased by 2 mg/kg/d over
5 days. Thereafter prednisone 0.3 mg/kg/d was gradually tapered to 0.1 mg/kg/d over 3 months.
Cyclosporin protocol:
- cyclosporin formulation: oil-based
Concomitant immunosuppression: steroids all patients; azathioprine to cyclosporin recipients according
to local practice.
- 10 centres - 1 mg/kg IV q 12 h and azathioprine 2 mg/kg IV once daily pre-op with initiation of
corticosteroids during procedure
- 1 centre - cyclosporin initiated at 2 mg/kg IV q 12 h x 1-2 days followed by 5 mg/kg po q 12 h; steroids
began IV q 12 h x 1-2 days followed by 5 mg/kg po q 12 h (steroids began intraoperatively)
- 1 centre - azathioprine 2 mg/kg IV/po once daily pre-op and continued during duration of study;
Minnesota antilymphoblast globulin 10 mg/kg od began POD#1 x 5 days; st steroids began intra-op,
cyclosporine started in POD#4.
- at all 12 centres - adult maintenance dose of steroids in cyclosporine group was a prednisone equivalent
of 200 mg once daily beginning POD#1 and dose tapered to 20 mg by day 6, 15 mg by day 60, 12.5 mg
by day 180 and 10 mg by day 360
- at all 12 centres - children prednisone or equivalent began at dose of 10 mg/kg/d on POD#1 and
decreased by 2 mg/kg/d over 5 days then adjusted at investigators discretion.
Outcomes - patient survival
- graft survival
- LOS in hospital
- acute rejection
- steroid resistant rejection
- withdrawal
- creatinine
- mean GFR
- de novo diabetes
- de novo dialysis
- PTLD.
Notes Follow-up: 12 months.
Other adverse events:
Event - tacrolimus (n =263); cyclosporin (n = 266)
alopecia - 20; 6
anaemia - 47; 38
anorexia - 34; 24
diarrhea - 72; 47
fever - 48; 56
headache - 64; 60
hirsutism - 7; 31
hypertension - 47; 56
nausea - 46; 56
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U. S. Study 1994 (Continued)
paraesthesia - 40; 30
pruritis - 36; 20
rash - 24; 19
tremor - 56; 46
vomiting 27; 15.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
Zervos 1998
Methods Generation of the allocation sequence: not clear.
Allocation concealment: not clear.
Blinding: not performed.
Follow-up: not clear. Outcomes appear to account for all patients but withdrawals not clearly specified.
Analysis: intention to treat.
Participants Country: USA, single centre.
Language: English.
Inclusion criteria: All male and female patients with hepatitis C virus undergoing liver transplantation.
Exclusion criteria / diagnoses: not specified.
Allocation: tacrolimus n = 35; cyclosporin n = 36
- tacrolimus n = 25
-cyclosporin = 24.
Interventions Tacrolimus protocol:
- 0.05 mg/kg po, adjusted to maintain a blood level of 15 ng/ml.
Cyclosporin protocol:
- cyclosporin formulation: microemulsion
- 3 mg/kg po, adjusted to maintain a blood level from 200 to 300 ng/ml.
Concomitant immunosuppression: steroids all patients.
Outcomes - patient survival
- graft survival
- acute rejection
- steroid resistant rejection
- withdrawal
- PTLD.
Notes Follow-up: 417 days median (range: from 25 to 625 days).
Other adverse events:
Event - tacrolimus (n = 25); cyclosporin (n = 25)
CMV - 5; 6
Infections - 17; 17
headaches - 2; 0
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Zervos 1998 (Continued)
Seizures - 0; 4
Aphasia - 0; 1.
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Unclear B - Unclear
Other adverse events: adverse events reported in studies that are not included in the outcomes section of this review are reported in
Notes.
CMV: cytomegalovirus
MMF: mycophenolate mofetil
PGE1: prostaglandin E1
plt: platelet count
LOS: length of stay
SBP: spontaneous bacterial peritonitis
od: once daily
po: per os or orally administered medication
q12h: every 12 hours
HIV: human immunodeficiency virus
NG: nasogastric
NJ: nasojejunal
SD: standard deviation
Characteristics of excluded studies [ordered by study ID]
Arnold 1995 Review of published studies.
Ericzon 1997 Specialised data only available at 10 days post-operatively.
Loinaz 2001 Locally derived data merged with local site analysis of data contributed to included multicentred study.
Trull 2002 Follow-up to 1 month postoperatively looking at specialised data.
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D A T A A N D A N A L Y S E S
Comparison 1. Cyclosporin versus tacrolimus
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
4 Steroid-resistent rejection 11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
5 Dialysis (de-novo requirement
post-transplantation)
5 873 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.64, 3.78]
6 Creatinine (umol/L) before
transplantation
2 672 Mean Difference (IV, Fixed, 95% CI) 1.36 [-3.05, 5.77]
7 Creatinine (umol/L) 12 months
after transplantation
2 672 Mean Difference (IV, Fixed, 95% CI) -2.67 [-9.55, 4.22]
8 Diabetes mellitus: initially
diagnosed after transplantation
11 3023 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
9 Post transplant
lymphoproliferative disease
7 1107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
10 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
Comparison 2. Stratified analysis, by cyclosporin formulation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
1.1 Tacrolimus versus oil-
based cyclosporin
3 1139 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.61, 1.04]
1.2 Tacrolimus versus micro-
emulsion cyclosporin
13 2674 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.73, 1.05]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
2.1 Tacrolimus versus oil-
based cyclosporin
3 1139 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.64, 0.99]
2.2 Tacrolimus versus micro-
emulsion cyclosporin
13 2674 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.65, 0.92]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
3.1 Tacrolimus versus oil-
based cyclosporin
3 1134 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.75, 0.92]
3.2 Tacrolimus versus
microemulsion cyclosporin
13 2652 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.75, 0.90]
4 Steroid-resistent rejection 11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
4.1 Tacrolimus versus oil-
based cyclosporin
3 1139 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.37, 0.66]
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4.2 Tacrolimus versus
microemulsion cyclosporin
8 1300 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.49, 0.92]
5 Dialysis (de-novo requirement
post-transplantation)
5 873 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.64, 3.78]
5.1 Tacrolimus versus oil-
based cyclosporin
2 610 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 15.83]
5.2 Tacrolimus versus
microemulsion cyclosporin
3 263 Risk Ratio (M-H, Fixed, 95% CI) 1.63 [0.63, 4.20]
6 Diabetes mellitus: initially
diagnosed after transplantation
11 3023 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
6.1 Tacrolimus versus oil-
based cyclosporin
2 1058 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.99, 1.29]
6.2 Tacrolimus versus
microemulsion cyclosporin
9 1965 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.20, 2.06]
7 Post transplant
lymphoproliferative disease
7 1107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
7.1 Tacrolimus versus oil-
based cyclosporin
2 610 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.72]
7.2 Tacrolimus versus
microemulsion cyclosporin
5 497 Risk Ratio (M-H, Fixed, 95% CI) 3.02 [0.62, 14.71]
8 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
8.1 Tacrolimus versus oil-
based cyclosporin
3 1212 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.63, 0.90]
8.2 Tacrolimus versus
microemulsion cyclosporin
10 1944 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.42, 0.66]
Comparison 3. Stratified analysis, by inclusion of children
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
1.1 Studies of children or
including children
2 714 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.61, 1.38]
1.2 Studies excluding children 14 3099 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.71, 0.99]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
2.1 Studies of children or
including children
2 714 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.59, 1.13]
2.2 Studies excluding children 14 3099 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.67, 0.90]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
3.1 Studies of children or
including children
2 716 Risk Ratio (M-H, Fixed, 95% CI) 0.87 [0.77, 0.99]
3.2 Studies excluding children 14 3070 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.74, 0.88]
4 Steroid-resistent rejection 11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
4.1 Studies of children or
including children
2 664 Risk Ratio (M-H, Fixed, 95% CI) 0.52 [0.38, 0.71]
4.2 Studies excluding children 9 1775 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.47, 0.84]
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5 Dialysis (de-novo requirement
post-transplantation)
5 873 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.64, 3.78]
5.1 Studies of children or
including children
1 529 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Studies excluding children 4 344 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.64, 3.78]
6 Diabetes mellitus: initially
diagnosed after transplantation
11 3023 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
6.1 Studies of children or
including children
2 714 Risk Ratio (M-H, Fixed, 95% CI) 1.88 [0.76, 4.65]
6.2 Studies excluding children 9 2309 Risk Ratio (M-H, Fixed, 95% CI) 1.25 [1.10, 1.42]
7 Post transplant
lymphoproliferative disease
7 1107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
7.1 Studies of children or
including children
2 714 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.42, 6.02]
7.2 Studies excluding children 5 393 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.07, 2.89]
8 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
8.1 Studies of children or
including children
2 710 Risk Ratio (M-H, Fixed, 95% CI) 0.72 [0.59, 0.89]
8.2 Studies excluding children 11 2446 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.50, 0.73]
Comparison 4. Stratified analysis, by studies reporting 12 month data
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
1.1 Studies reporting less than
12 month data
2 214 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [0.53, 2.82]
1.2 Studies reporting 12
month data
14 3599 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.72, 0.98]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
2.1 Studies reporting less than
12 month data
3 709 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.70, 1.53]
2.2 Studies reporting 12
month data
13 3104 Risk Ratio (M-H, Fixed, 95% CI) 0.75 [0.65, 0.87]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
3.1 Studies reporting less than
12 month data
2 192 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.59, 1.16]
3.2 Studies reporting 12
month data
14 3594 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.89]
4 Steroid-resistent rejection 11 2573 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.70]
4.1 Studies reporting less than
12 month data
1 134 Risk Ratio (M-H, Fixed, 95% CI) 0.42 [0.14, 1.29]
4.2 Studies reporting 12
month data
11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
6 Diabetes mellitus: initially
diagnosed after transplantation
11 3023 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
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6.1 Studies reporting less than
12 month data
2 192 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.31, 3.92]
6.2 Studies reporting 12
month data
9 2831 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
8 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
8.1 Studies reporting less than
12 month data
1 57 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.57, 3.89]
8.2 Studies reporting 12
month data
12 3099 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.55, 0.73]
Comparison 5. Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
1.1 Studies confined to
patients with hepatitis C virus
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.44, 1.56]
1.2 Studies including hepatitis
C virus and other diagnoses
14 3685 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
2.1 Studies confined to
patients with hepatitis C virus
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.40, 1.19]
2.2 Studies including hepatitis
C virus and other diagnoses
14 3685 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.69, 0.90]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
3.1 Studies confined to
patients with hepatitis C virus
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.38, 1.02]
3.2 Studies including hepatitis
C virus and other diagnoses
14 3658 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.77, 0.89]
4 Steroid-resistent rejection 11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
4.1 Studies confined to
patients with hepatitis C virus
1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.01, 7.50]
4.2 Studies including hepatitis
C virus and other diagnoses
10 2390 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.47, 0.71]
5 Post transplant
lymphoproliferative disease
7 1107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
5.1 Studies confined to
patients with hepatitis C virus
1 49 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Studies including hepatitis
C virus and other diagnoses
6 1058 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
6 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
6.1 Studies confined to
patients with hepatitis C virus
2 128 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.18, 1.02]
6.2 Studies including hepatitis
C virus and other diagnoses
11 3028 Risk Ratio (M-H, Fixed, 95% CI) 0.66 [0.57, 0.76]
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Comparison 6. Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mortality 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.73, 0.99]
1.1 Concomittant
azathioprine
4 868 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.51, 0.92]
1.2 Concomitant azathioprine
(some centres only)
1 495 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.61, 1.44]
1.3 Concomitant azathioprine
with cyclosporin only (some
centres)
5 2006 Risk Ratio (M-H, Fixed, 95% CI) 0.94 [0.76, 1.16]
1.4 Concomitant
mycophenolate mofetil
3 250 Risk Ratio (M-H, Fixed, 95% CI) 1.02 [0.37, 2.80]
1.5 No concomitant
azathioprine or mycopholic
mofetil
3 194 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.39, 1.24]
2 Graft loss 16 3813 Risk Ratio (M-H, Fixed, 95% CI) 0.78 [0.68, 0.89]
2.1 Studies with concomittant
azathioprine
4 868 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.49, 0.84]
2.2 Concomitant azathioprine
(some centres only)
1 495 Risk Ratio (M-H, Fixed, 95% CI) 1.10 [0.67, 1.80]
2.3 Concomitant azathioprine
with cyclosporine only (some
centres)
5 2006 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.72, 1.03]
2.4 Concomitant
mycophenolate mofetil
3 250 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.30, 1.60]
2.5 No concomitant
azathioprine or mycophenolate
mofetil
3 194 Risk Ratio (M-H, Fixed, 95% CI) 0.55 [0.35, 0.88]
3 Acute rejection 16 3786 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.77, 0.88]
3.1 Concomitant azathioprine 4 868 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.72, 0.95]
3.2 Concomitant azathioprine
(some centres only)
1 495 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.33, 1.38]
3.3 Concomitant azathioprine
with cyclosporin only (some
centres)
5 1999 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.78, 0.93]
3.4 Concomitant
mycophenolate mofetil
3 237 Risk Ratio (M-H, Fixed, 95% CI) 0.77 [0.56, 1.06]
3.5 No concomitant
azathioprine or mycophenolate
3 187 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.53, 0.86]
4 Steroid-resistent rejection 11 2439 Risk Ratio (M-H, Fixed, 95% CI) 0.57 [0.46, 0.71]
4.1 Concomitant azathioprine 2 183 Risk Ratio (M-H, Fixed, 95% CI) 0.43 [0.15, 1.26]
4.2 Concomitant azathioprine
with cyclosporin only (some
centres only)
5 1947 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.46, 0.74]
4.3 Concomitant
mycophenolate mofetil
2 179 Risk Ratio (M-H, Fixed, 95% CI) 0.53 [0.20, 1.37]
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4.4 No concomitant
azathioprine or mycophenolate
mofetil
2 130 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.29, 1.31]
5 Dialysis (de-novo requirement
post-transplantation)
5 873 Risk Ratio (M-H, Fixed, 95% CI) 1.55 [0.64, 3.78]
5.1 Concomitant azathioprine 2 183 Risk Ratio (M-H, Fixed, 95% CI) 1.56 [0.56, 4.39]
5.2 Concomitant azathioprine
with cyclosporin only (some
centres only)
1 529 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
5.3 Concomitant
mycophenolate mofetil
1 80 Risk Ratio (M-H, Fixed, 95% CI) 2.0 [0.19, 21.18]
5.4 No concomitant
azathioprine or mycophenolate
mofetil
1 81 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 15.83]
6 Diabetes mellitus: initially
diagnosed after transplantation
11 3023 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [1.12, 1.44]
6.1 Concomitant azathioprine 3 789 Risk Ratio (M-H, Fixed, 95% CI) 1.57 [1.06, 2.33]
6.2 Concomitant azathioprine
with cyclosporin only (some
centres only)
5 1997 Risk Ratio (M-H, Fixed, 95% CI) 1.22 [1.07, 1.40]
6.3 Concomitant
mycophenolate mofetil
3 237 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [0.52, 2.49]
7 Post transplant
lymphoproliferative disease
7 1107 Risk Ratio (M-H, Fixed, 95% CI) 1.01 [0.36, 2.86]
7.1 Concomitant azathioprine 2 183 Risk Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 Concomitant azathioprine
with cyclosporin only (some
centres only)
2 714 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.42, 6.02]
7.3 Concomitant
mycophenolate mofetil
1 80 Risk Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 15.44]
7.4 No concomitant
azathioprine or mycophenolate
mofetil
2 130 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.01, 4.14]
8 Patients withdrawn from
tacrolimus or cyclosporin
13 3156 Risk Ratio (M-H, Fixed, 95% CI) 0.65 [0.57, 0.74]
8.1 Concomitant azathioprine 4 865 Risk Ratio (M-H, Fixed, 95% CI) 0.68 [0.48, 0.96]
8.2 Concomitant azathioprine
with cyclosporin only (some
centres only)
4 1854 Risk Ratio (M-H, Fixed, 95% CI) 0.81 [0.69, 0.96]
8.3 Concomitant
mycophenolate mofetil
3 234 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.36, 0.96]
8.4 No concomitant
azathioprine or mycophenolate
mofetil
2 203 Risk Ratio (M-H, Fixed, 95% CI) 0.02 [0.00, 0.12]
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Analysis 1.1. Comparison 1 Cyclosporin versus tacrolimus, Outcome 1 Mortality.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 1.2. Comparison 1 Cyclosporin versus tacrolimus, Outcome 2 Graft loss.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Analysis 1.3. Comparison 1 Cyclosporin versus tacrolimus, Outcome 3 Acute rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 3 Acute rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimus), 888 (cyclosporin)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Analysis 1.4. Comparison 1 Cyclosporin versus tacrolimus, Outcome 4 Steroid-resistent rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 2/264 14/265 7.1 % 0.14 [ 0.03, 0.62 ]
Fisher 1998 0/49 1/50 0.8 % 0.34 [ 0.01, 8.15 ]
Fung 1991 8/41 12/40 6.2 % 0.65 [ 0.30, 1.42 ]
Greig 2003 4/71 7/72 3.5 % 0.58 [ 0.18, 1.89 ]
Kelly 2004 5/42 24/93 7.6 % 0.46 [ 0.19, 1.13 ]
Klupp 1999 5/40 9/40 4.6 % 0.56 [ 0.20, 1.51 ]
Muehlbacher 2001 39/313 42/307 21.5 % 0.91 [ 0.61, 1.37 ]
Therapondos 2002 0/20 3/20 1.8 % 0.14 [ 0.01, 2.60 ]
Timmermann 2002 4/65 10/69 4.9 % 0.42 [ 0.14, 1.29 ]
U. S. Study 1994 43/263 82/266 41.4 % 0.53 [ 0.38, 0.74 ]
Zervos 1998 0/25 1/24 0.8 % 0.32 [ 0.01, 7.50 ]
Total (95% CI) 1193 1246 100.0 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
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Analysis 1.5. Comparison 1 Cyclosporin versus tacrolimus, Outcome 5 Dialysis (de-novo requirement post-
transplantation).
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 5 Dialysis (de-novo requirement post-transplantation)
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fung 1991 1/40 1/41 1.03 [ 0.07, 15.83 ]
Greig 2003 7/71 5/72 1.42 [ 0.47, 4.26 ]
Klupp 1999 2/40 1/40 2.00 [ 0.19, 21.18 ]
Therapondos 2002 1/20 0/20 3.00 [ 0.13, 69.52 ]
U. S. Study 1994 0/263 0/266 0.0 [ 0.0, 0.0 ]
Total (95% CI) 434 439 1.55 [ 0.64, 3.78 ]
Total events: 11 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 1.6. Comparison 1 Cyclosporin versus tacrolimus, Outcome 6 Creatinine (umol/L) before
transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 6 Creatinine (umol/L) before transplantation
Study or subgroup tacrolimus cyclosporin Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Greig 2003 71 70 (20) 72 67 (20) 45.3 % 3.00 [ -3.56, 9.56 ]
U. S. Study 1994 263 88 (35) 266 88 (35) 54.7 % 0.0 [ -5.97, 5.97 ]
Total (95% CI) 334 338 100.0 % 1.36 [ -3.05, 5.77 ]
Heterogeneity: Chi2 = 0.44, df = 1 (P = 0.51); I2 =0.0%
Test for overall effect: Z = 0.60 (P = 0.55)
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Analysis 1.7. Comparison 1 Cyclosporin versus tacrolimus, Outcome 7 Creatinine (umol/L) 12 months after
transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 7 Creatinine (umol/L) 12 months after transplantation
Study or subgroup tacrolimus cyclosporine Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Greig 2003 71 120 (32) 72 137 (68) 15.7 % -17.00 [ -34.38, 0.38 ]
U. S. Study 1994 263 133 (44) 266 133 (44) 84.3 % 0.0 [ -7.50, 7.50 ]
Total (95% CI) 334 338 100.0 % -2.67 [ -9.55, 4.22 ]
Heterogeneity: Chi2 = 3.10, df = 1 (P = 0.08); I2 =68%
Test for overall effect: Z = 0.76 (P = 0.45)
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Analysis 1.8. Comparison 1 Cyclosporin versus tacrolimus, Outcome 8 Diabetes mellitus: initially diagnosed
after transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 8 Diabetes mellitus: initially diagnosed after transplantation
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 177/264 162/265 66.7 % 1.10 [ 0.97, 1.25 ]
Fisher 1998 7/49 7/50 2.9 % 1.02 [ 0.39, 2.69 ]
Greig 2003 17/71 20/72 8.2 % 0.86 [ 0.49, 1.50 ]
Kelly 2004 2/92 2/93 0.8 % 1.01 [ 0.15, 7.02 ]
Klupp 1999 3/40 3/40 1.2 % 1.00 [ 0.21, 4.66 ]
Muehlbacher 2001 49/313 25/307 10.4 % 1.92 [ 1.22, 3.03 ]
O’Grady 2002 33/301 14/305 5.7 % 2.39 [ 1.30, 4.37 ]
Stegall 1997 1/25 0/33 0.2 % 3.92 [ 0.17, 92.43 ]
Therapondos 2002 3/20 0/20 0.2 % 7.00 [ 0.38, 127.32 ]
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(. . . Continued)
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Timmermann 2002 3/65 4/69 1.6 % 0.80 [ 0.19, 3.42 ]
U. S. Study 1994 11/263 5/266 2.1 % 2.23 [ 0.78, 6.32 ]
Total (95% CI) 1503 1520 100.0 % 1.27 [ 1.12, 1.44 ]
Total events: 306 (tacrolimus), 242 (cyclosporin)
Heterogeneity: Chi2 = 17.92, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 3.70 (P = 0.00022)
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Analysis 1.9. Comparison 1 Cyclosporin versus tacrolimus, Outcome 9 Post transplant lymphoproliferative
disease.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 9 Post transplant lymphoproliferative disease
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Fung 1991 0/40 2/41 0.20 [ 0.01, 4.14 ]
Greig 2003 0/71 0/72 0.0 [ 0.0, 0.0 ]
Kelly 2004 5/92 1/93 5.05 [ 0.60, 42.43 ]
Klupp 1999 1/40 1/40 1.00 [ 0.06, 15.44 ]
Therapondos 2002 0/20 0/20 0.0 [ 0.0, 0.0 ]
U. S. Study 1994 0/263 2/266 0.20 [ 0.01, 4.19 ]
Zervos 1998 0/25 0/24 0.0 [ 0.0, 0.0 ]
Total (95% CI) 551 556 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 1.10. Comparison 1 Cyclosporin versus tacrolimus, Outcome 10 Patients withdrawn from
tacrolimus or cyclosporin.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 1 Cyclosporin versus tacrolimus
Outcome: 10 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 2.1. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 1 Mortality.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Subtotal (95% CI) 568 571 33.5 % 0.80 [ 0.61, 1.04 ]
Total events: 80 (tacrolimus), 101 (cyclosporin)
Heterogeneity: Chi2 = 1.62, df = 2 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 1.67 (P = 0.095)
2 Tacrolimus versus micro-emulsion cyclosporin
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Subtotal (95% CI) 1331 1343 66.5 % 0.87 [ 0.73, 1.05 ]
Total events: 174 (tacrolimus), 201 (cyclosporin)
Heterogeneity: Chi2 = 9.39, df = 12 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.41 (P = 0.16)
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 2.2. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 2 Graft loss.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Subtotal (95% CI) 568 571 36.0 % 0.80 [ 0.64, 0.99 ]
Total events: 112 (tacrolimus), 141 (cyclosporin)
Heterogeneity: Chi2 = 3.18, df = 2 (P = 0.20); I2 =37%
Test for overall effect: Z = 2.02 (P = 0.044)
2 Tacrolimus versus micro-emulsion cyclosporin
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Subtotal (95% CI) 1331 1343 64.0 % 0.77 [ 0.65, 0.92 ]
Total events: 192 (tacrolimus), 251 (cyclosporin)
Heterogeneity: Chi2 = 12.91, df = 12 (P = 0.38); I2 =7%
Test for overall effect: Z = 2.98 (P = 0.0029)
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Analysis 2.3. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 3 Acute rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 3 Acute rejection
Study or subgroup tacrolimus cyclosporine Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Subtotal (95% CI) 570 564 39.1 % 0.83 [ 0.75, 0.92 ]
Total events: 288 (tacrolimus), 344 (cyclosporine)
Heterogeneity: Chi2 = 7.54, df = 2 (P = 0.02); I2 =73%
Test for overall effect: Z = 3.60 (P = 0.00032)
2 Tacrolimus versus microemulsion cyclosporin
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Subtotal (95% CI) 1315 1337 60.9 % 0.82 [ 0.75, 0.90 ]
Total events: 440 (tacrolimus), 544 (cyclosporine)
Heterogeneity: Chi2 = 12.54, df = 12 (P = 0.40); I2 =4%
Test for overall effect: Z = 4.10 (P = 0.000042)
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimus), 888 (cyclosporine)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Analysis 2.4. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 4 Steroid-resistent
rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 2/264 14/265 7.1 % 0.14 [ 0.03, 0.62 ]
Fung 1991 8/41 12/40 6.2 % 0.65 [ 0.30, 1.42 ]
U. S. Study 1994 43/263 82/266 41.4 % 0.53 [ 0.38, 0.74 ]
Subtotal (95% CI) 568 571 54.6 % 0.49 [ 0.37, 0.66 ]
Total events: 53 (tacrolimus), 108 (cyclosporin)
Heterogeneity: Chi2 = 3.37, df = 2 (P = 0.19); I2 =41%
Test for overall effect: Z = 4.69 (P < 0.00001)
2 Tacrolimus versus microemulsion cyclosporin
Fisher 1998 0/49 1/50 0.8 % 0.34 [ 0.01, 8.15 ]
Greig 2003 4/71 7/72 3.5 % 0.58 [ 0.18, 1.89 ]
Kelly 2004 5/42 24/93 7.6 % 0.46 [ 0.19, 1.13 ]
Klupp 1999 5/40 9/40 4.6 % 0.56 [ 0.20, 1.51 ]
Muehlbacher 2001 39/313 42/307 21.5 % 0.91 [ 0.61, 1.37 ]
Therapondos 2002 0/20 3/20 1.8 % 0.14 [ 0.01, 2.60 ]
Timmermann 2002 4/65 10/69 4.9 % 0.42 [ 0.14, 1.29 ]
Zervos 1998 0/25 1/24 0.8 % 0.32 [ 0.01, 7.50 ]
Subtotal (95% CI) 625 675 45.4 % 0.67 [ 0.49, 0.92 ]
Total events: 57 (tacrolimus), 97 (cyclosporin)
Heterogeneity: Chi2 = 5.17, df = 7 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 2.52 (P = 0.012)
Total (95% CI) 1193 1246 100.0 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
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Analysis 2.5. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 5 Dialysis (de-novo
requirement post-transplantation).
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 5 Dialysis (de-novo requirement post-transplantation)
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
Fung 1991 1/40 1/41 1.03 [ 0.07, 15.83 ]
U. S. Study 1994 0/263 0/266 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 303 307 1.03 [ 0.07, 15.83 ]
Total events: 1 (tacrolimus), 1 (cyclosporin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.02 (P = 0.99)
2 Tacrolimus versus microemulsion cyclosporin
Greig 2003 7/71 5/72 1.42 [ 0.47, 4.26 ]
Klupp 1999 2/40 1/40 2.00 [ 0.19, 21.18 ]
Therapondos 2002 1/20 0/20 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 131 132 1.63 [ 0.63, 4.20 ]
Total events: 10 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 0.23, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Total (95% CI) 434 439 1.55 [ 0.64, 3.78 ]
Total events: 11 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 2.6. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 6 Diabetes mellitus:
initially diagnosed after transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 6 Diabetes mellitus: initially diagnosed after transplantation
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 177/264 162/265 66.7 % 1.10 [ 0.97, 1.25 ]
U. S. Study 1994 11/263 5/266 2.1 % 2.23 [ 0.78, 6.32 ]
Subtotal (95% CI) 527 531 68.8 % 1.13 [ 0.99, 1.29 ]
Total events: 188 (tacrolimus), 167 (cyclosporin)
Heterogeneity: Chi2 = 1.83, df = 1 (P = 0.18); I2 =45%
Test for overall effect: Z = 1.85 (P = 0.064)
2 Tacrolimus versus microemulsion cyclosporin
Fisher 1998 7/49 7/50 2.9 % 1.02 [ 0.39, 2.69 ]
Greig 2003 17/71 20/72 8.2 % 0.86 [ 0.49, 1.50 ]
Kelly 2004 2/92 2/93 0.8 % 1.01 [ 0.15, 7.02 ]
Klupp 1999 3/40 3/40 1.2 % 1.00 [ 0.21, 4.66 ]
Muehlbacher 2001 49/313 25/307 10.4 % 1.92 [ 1.22, 3.03 ]
O’Grady 2002 33/301 14/305 5.7 % 2.39 [ 1.30, 4.37 ]
Stegall 1997 1/25 0/33 0.2 % 3.92 [ 0.17, 92.43 ]
Therapondos 2002 3/20 0/20 0.2 % 7.00 [ 0.38, 127.32 ]
Timmermann 2002 3/65 4/69 1.6 % 0.80 [ 0.19, 3.42 ]
Subtotal (95% CI) 976 989 31.2 % 1.57 [ 1.20, 2.06 ]
Total events: 118 (tacrolimus), 75 (cyclosporin)
Heterogeneity: Chi2 = 10.53, df = 8 (P = 0.23); I2 =24%
Test for overall effect: Z = 3.29 (P = 0.00099)
Total (95% CI) 1503 1520 100.0 % 1.27 [ 1.12, 1.44 ]
Total events: 306 (tacrolimus), 242 (cyclosporin)
Heterogeneity: Chi2 = 17.92, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 3.70 (P = 0.00022)
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Analysis 2.7. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 7 Post transplant
lymphoproliferative disease.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 7 Post transplant lymphoproliferative disease
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
Fung 1991 0/40 2/41 0.20 [ 0.01, 4.14 ]
U. S. Study 1994 0/263 2/266 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 303 307 0.20 [ 0.02, 1.72 ]
Total events: 0 (tacrolimus), 4 (cyclosporin)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.46 (P = 0.14)
2 Tacrolimus versus microemulsion cyclosporin
Greig 2003 0/71 0/72 0.0 [ 0.0, 0.0 ]
Kelly 2004 5/92 1/93 5.05 [ 0.60, 42.43 ]
Klupp 1999 1/40 1/40 1.00 [ 0.06, 15.44 ]
Therapondos 2002 0/20 0/20 0.0 [ 0.0, 0.0 ]
Zervos 1998 0/25 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 248 249 3.02 [ 0.62, 14.71 ]
Total events: 6 (tacrolimus), 2 (cyclosporin)
Heterogeneity: Chi2 = 0.85, df = 1 (P = 0.36); I2 =0.0%
Test for overall effect: Z = 1.37 (P = 0.17)
Total (95% CI) 551 556 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 2.8. Comparison 2 Stratified analysis, by cyclosporin formulation, Outcome 8 Patients withdrawn
from tacrolimus or cyclosporin.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 2 Stratified analysis, by cyclosporin formulation
Outcome: 8 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Tacrolimus versus oil-based cyclosporin
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 606 606 54.5 % 0.75 [ 0.63, 0.90 ]
Total events: 160 (tacrolimus), 213 (cyclosporin)
Heterogeneity: Chi2 = 23.71, df = 2 (P<0.00001); I2 =92%
Test for overall effect: Z = 3.20 (P = 0.0014)
2 Tacrolimus versus microemulsion cyclosporin
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Subtotal (95% CI) 967 977 45.5 % 0.53 [ 0.42, 0.66 ]
Total events: 92 (tacrolimus), 179 (cyclosporin)
Heterogeneity: Chi2 = 18.74, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 5.56 (P < 0.00001)
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 3.1. Comparison 3 Stratified analysis, by inclusion of children, Outcome 1 Mortality.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Subtotal (95% CI) 355 359 13.9 % 0.91 [ 0.61, 1.38 ]
Total events: 38 (tacrolimus), 42 (cyclosporin)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
2 Studies excluding children
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Subtotal (95% CI) 1544 1555 86.1 % 0.84 [ 0.71, 0.99 ]
Total events: 216 (tacrolimus), 260 (cyclosporin)
Heterogeneity: Chi2 = 11.05, df = 13 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
0.01 0.1 1 10 100
Favours tacrolimus Favours cyclosporin
52Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.2. Comparison 3 Stratified analysis, by inclusion of children, Outcome 2 Graft loss.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Subtotal (95% CI) 355 359 17.3 % 0.82 [ 0.59, 1.13 ]
Total events: 55 (tacrolimus), 68 (cyclosporin)
Heterogeneity: Chi2 = 1.02, df = 1 (P = 0.31); I2 =2%
Test for overall effect: Z = 1.22 (P = 0.22)
2 Studies excluding children
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Subtotal (95% CI) 1544 1555 82.7 % 0.77 [ 0.67, 0.90 ]
Total events: 249 (tacrolimus), 324 (cyclosporin)
Heterogeneity: Chi2 = 15.04, df = 13 (P = 0.30); I2 =14%
Test for overall effect: Z = 3.40 (P = 0.00068)
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Analysis 3.3. Comparison 3 Stratified analysis, by inclusion of children, Outcome 3 Acute rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 3 Acute rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Subtotal (95% CI) 357 359 25.0 % 0.87 [ 0.77, 0.99 ]
Total events: 192 (tacrolimus), 222 (cyclosporin)
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.20 (P = 0.028)
2 Studies excluding children
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Subtotal (95% CI) 1528 1542 75.0 % 0.81 [ 0.74, 0.88 ]
Total events: 536 (tacrolimus), 666 (cyclosporin)
Heterogeneity: Chi2 = 18.25, df = 13 (P = 0.15); I2 =29%
Test for overall effect: Z = 4.98 (P < 0.00001)
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimus), 888 (cyclosporin)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Analysis 3.4. Comparison 3 Stratified analysis, by inclusion of children, Outcome 4 Steroid-resistent
rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 5/42 24/93 7.6 % 0.46 [ 0.19, 1.13 ]
U. S. Study 1994 43/263 82/266 41.4 % 0.53 [ 0.38, 0.74 ]
Subtotal (95% CI) 305 359 48.9 % 0.52 [ 0.38, 0.71 ]
Total events: 48 (tacrolimus), 106 (cyclosporin)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 4.16 (P = 0.000032)
2 Studies excluding children
European Study 1994 2/264 14/265 7.1 % 0.14 [ 0.03, 0.62 ]
Fisher 1998 0/49 1/50 0.8 % 0.34 [ 0.01, 8.15 ]
Fung 1991 8/41 12/40 6.2 % 0.65 [ 0.30, 1.42 ]
Greig 2003 4/71 7/72 3.5 % 0.58 [ 0.18, 1.89 ]
Klupp 1999 5/40 9/40 4.6 % 0.56 [ 0.20, 1.51 ]
Muehlbacher 2001 39/313 42/307 21.5 % 0.91 [ 0.61, 1.37 ]
Therapondos 2002 0/20 3/20 1.8 % 0.14 [ 0.01, 2.60 ]
Timmermann 2002 4/65 10/69 4.9 % 0.42 [ 0.14, 1.29 ]
Zervos 1998 0/25 1/24 0.8 % 0.32 [ 0.01, 7.50 ]
Subtotal (95% CI) 888 887 51.1 % 0.63 [ 0.47, 0.84 ]
Total events: 62 (tacrolimus), 99 (cyclosporin)
Heterogeneity: Chi2 = 8.97, df = 8 (P = 0.34); I2 =11%
Test for overall effect: Z = 3.10 (P = 0.0019)
Total (95% CI) 1193 1246 100.0 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
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Analysis 3.5. Comparison 3 Stratified analysis, by inclusion of children, Outcome 5 Dialysis (de-novo
requirement post-transplantation).
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 5 Dialysis (de-novo requirement post-transplantation)
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
U. S. Study 1994 0/263 0/266 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 263 266 0.0 [ 0.0, 0.0 ]
Total events: 0 (tacrolimus), 0 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Studies excluding children
Fung 1991 1/40 1/41 1.03 [ 0.07, 15.83 ]
Greig 2003 7/71 5/72 1.42 [ 0.47, 4.26 ]
Klupp 1999 2/40 1/40 2.00 [ 0.19, 21.18 ]
Therapondos 2002 1/20 0/20 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 171 173 1.55 [ 0.64, 3.78 ]
Total events: 11 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
Total (95% CI) 434 439 1.55 [ 0.64, 3.78 ]
Total events: 11 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 3.6. Comparison 3 Stratified analysis, by inclusion of children, Outcome 6 Diabetes mellitus:
initially diagnosed after transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 6 Diabetes mellitus: initially diagnosed after transplantation
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 2/92 2/93 0.8 % 1.01 [ 0.15, 7.02 ]
U. S. Study 1994 11/263 5/266 2.1 % 2.23 [ 0.78, 6.32 ]
Subtotal (95% CI) 355 359 2.9 % 1.88 [ 0.76, 4.65 ]
Total events: 13 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.36 (P = 0.17)
2 Studies excluding children
European Study 1994 177/264 162/265 66.7 % 1.10 [ 0.97, 1.25 ]
Fisher 1998 7/49 7/50 2.9 % 1.02 [ 0.39, 2.69 ]
Greig 2003 17/71 20/72 8.2 % 0.86 [ 0.49, 1.50 ]
Klupp 1999 3/40 3/40 1.2 % 1.00 [ 0.21, 4.66 ]
Muehlbacher 2001 49/313 25/307 10.4 % 1.92 [ 1.22, 3.03 ]
O’Grady 2002 33/301 14/305 5.7 % 2.39 [ 1.30, 4.37 ]
Stegall 1997 1/25 0/33 0.2 % 3.92 [ 0.17, 92.43 ]
Therapondos 2002 3/20 0/20 0.2 % 7.00 [ 0.38, 127.32 ]
Timmermann 2002 3/65 4/69 1.6 % 0.80 [ 0.19, 3.42 ]
Subtotal (95% CI) 1148 1161 97.1 % 1.25 [ 1.10, 1.42 ]
Total events: 293 (tacrolimus), 235 (cyclosporin)
Heterogeneity: Chi2 = 16.08, df = 8 (P = 0.04); I2 =50%
Test for overall effect: Z = 3.47 (P = 0.00053)
Total (95% CI) 1503 1520 100.0 % 1.27 [ 1.12, 1.44 ]
Total events: 306 (tacrolimus), 242 (cyclosporin)
Heterogeneity: Chi2 = 17.92, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 3.70 (P = 0.00022)
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Analysis 3.7. Comparison 3 Stratified analysis, by inclusion of children, Outcome 7 Post transplant
lymphoproliferative disease.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 7 Post transplant lymphoproliferative disease
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 5/92 1/93 5.05 [ 0.60, 42.43 ]
U. S. Study 1994 0/263 2/266 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 355 359 1.59 [ 0.42, 6.02 ]
Total events: 5 (tacrolimus), 3 (cyclosporin)
Heterogeneity: Chi2 = 2.91, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.68 (P = 0.50)
2 Studies excluding children
Fung 1991 0/40 2/41 0.20 [ 0.01, 4.14 ]
Greig 2003 0/71 0/72 0.0 [ 0.0, 0.0 ]
Klupp 1999 1/40 1/40 1.00 [ 0.06, 15.44 ]
Therapondos 2002 0/20 0/20 0.0 [ 0.0, 0.0 ]
Zervos 1998 0/25 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 196 197 0.43 [ 0.07, 2.89 ]
Total events: 1 (tacrolimus), 3 (cyclosporin)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
Total (95% CI) 551 556 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 3.8. Comparison 3 Stratified analysis, by inclusion of children, Outcome 8 Patients withdrawn from
tacrolimus or cyclosporin.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 3 Stratified analysis, by inclusion of children
Outcome: 8 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies of children or including children
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 354 356 36.9 % 0.72 [ 0.59, 0.89 ]
Total events: 104 (tacrolimus), 145 (cyclosporin)
Heterogeneity: Chi2 = 4.51, df = 1 (P = 0.03); I2 =78%
Test for overall effect: Z = 3.12 (P = 0.0018)
2 Studies excluding children
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Subtotal (95% CI) 1219 1227 63.1 % 0.61 [ 0.50, 0.73 ]
Total events: 148 (tacrolimus), 247 (cyclosporin)
Heterogeneity: Chi2 = 50.89, df = 10 (P<0.00001); I2 =80%
Test for overall effect: Z = 5.30 (P < 0.00001)
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 4.1. Comparison 4 Stratified analysis, by studies reporting 12 month data, Outcome 1 Mortality.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
Subtotal (95% CI) 107 107 3.0 % 1.22 [ 0.53, 2.82 ]
Total events: 11 (tacrolimus), 9 (cyclosporin)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.47 (P = 0.64)
2 Studies reporting 12 month data
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Subtotal (95% CI) 1792 1807 97.0 % 0.84 [ 0.72, 0.98 ]
Total events: 243 (tacrolimus), 293 (cyclosporin)
Heterogeneity: Chi2 = 10.09, df = 13 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 2.25 (P = 0.025)
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 4.2. Comparison 4 Stratified analysis, by studies reporting 12 month data, Outcome 2 Graft loss.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
Subtotal (95% CI) 352 357 10.9 % 1.04 [ 0.70, 1.53 ]
Total events: 44 (tacrolimus), 43 (cyclosporin)
Heterogeneity: Chi2 = 1.23, df = 2 (P = 0.54); I2 =0.0%
Test for overall effect: Z = 0.17 (P = 0.86)
2 Studies reporting 12 month data
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Subtotal (95% CI) 1547 1557 89.1 % 0.75 [ 0.65, 0.87 ]
Total events: 260 (tacrolimus), 349 (cyclosporin)
Heterogeneity: Chi2 = 13.00, df = 12 (P = 0.37); I2 =8%
Test for overall effect: Z = 3.93 (P = 0.000084)
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 3 Acute rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
Subtotal (95% CI) 91 101 5.0 % 0.83 [ 0.59, 1.16 ]
Total events: 35 (tacrolimus), 47 (cyclosporin)
Heterogeneity: Chi2 = 0.12, df = 1 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.11 (P = 0.27)
2 Studies reporting 12 month data
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Subtotal (95% CI) 1794 1800 95.0 % 0.82 [ 0.77, 0.89 ]
Total events: 693 (tacrolimus), 841 (cyclosporin)
Heterogeneity: Chi2 = 19.97, df = 13 (P = 0.10); I2 =35%
Test for overall effect: Z = 5.32 (P < 0.00001)
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimus), 888 (cyclosporin)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Timmermann 2002 4/65 10/69 4.7 % 0.42 [ 0.14, 1.29 ]
Subtotal (95% CI) 65 69 4.7 % 0.42 [ 0.14, 1.29 ]
Total events: 4 (tacrolimus), 10 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
2 Studies reporting 12 month data
European Study 1994 2/264 14/265 6.8 % 0.14 [ 0.03, 0.62 ]
Fisher 1998 0/49 1/50 0.7 % 0.34 [ 0.01, 8.15 ]
Fung 1991 8/41 12/40 5.9 % 0.65 [ 0.30, 1.42 ]
Greig 2003 4/71 7/72 3.4 % 0.58 [ 0.18, 1.89 ]
Kelly 2004 5/42 24/93 7.2 % 0.46 [ 0.19, 1.13 ]
Klupp 1999 5/40 9/40 4.4 % 0.56 [ 0.20, 1.51 ]
Muehlbacher 2001 39/313 42/307 20.5 % 0.91 [ 0.61, 1.37 ]
Therapondos 2002 0/20 3/20 1.7 % 0.14 [ 0.01, 2.60 ]
Timmermann 2002 4/65 10/69 4.7 % 0.42 [ 0.14, 1.29 ]
U. S. Study 1994 43/263 82/266 39.4 % 0.53 [ 0.38, 0.74 ]
Zervos 1998 0/25 1/24 0.7 % 0.32 [ 0.01, 7.50 ]
Subtotal (95% CI) 1193 1246 95.3 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
Total (95% CI) 1258 1315 100.0 % 0.57 [ 0.46, 0.70 ]
Total events: 114 (tacrolimus), 215 (cyclosporin)
Heterogeneity: Chi2 = 10.67, df = 11 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 5.31 (P < 0.00001)
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mellitus: initially diagnosed after transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 6 Diabetes mellitus: initially diagnosed after transplantation
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Stegall 1997 1/25 0/33 0.2 % 3.92 [ 0.17, 92.43 ]
Timmermann 2002 3/65 4/69 1.6 % 0.80 [ 0.19, 3.42 ]
Subtotal (95% CI) 90 102 1.8 % 1.11 [ 0.31, 3.92 ]
Total events: 4 (tacrolimus), 4 (cyclosporin)
Heterogeneity: Chi2 = 0.81, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 0.16 (P = 0.87)
2 Studies reporting 12 month data
European Study 1994 177/264 162/265 66.7 % 1.10 [ 0.97, 1.25 ]
Fisher 1998 7/49 7/50 2.9 % 1.02 [ 0.39, 2.69 ]
Greig 2003 17/71 20/72 8.2 % 0.86 [ 0.49, 1.50 ]
Kelly 2004 2/92 2/93 0.8 % 1.01 [ 0.15, 7.02 ]
Klupp 1999 3/40 3/40 1.2 % 1.00 [ 0.21, 4.66 ]
Muehlbacher 2001 49/313 25/307 10.4 % 1.92 [ 1.22, 3.03 ]
O’Grady 2002 33/301 14/305 5.7 % 2.39 [ 1.30, 4.37 ]
Therapondos 2002 3/20 0/20 0.2 % 7.00 [ 0.38, 127.32 ]
U. S. Study 1994 11/263 5/266 2.1 % 2.23 [ 0.78, 6.32 ]
Subtotal (95% CI) 1413 1418 98.2 % 1.27 [ 1.12, 1.44 ]
Total events: 302 (tacrolimus), 238 (cyclosporin)
Heterogeneity: Chi2 = 17.14, df = 8 (P = 0.03); I2 =53%
Test for overall effect: Z = 3.73 (P = 0.00019)
Total (95% CI) 1503 1520 100.0 % 1.27 [ 1.12, 1.44 ]
Total events: 306 (tacrolimus), 242 (cyclosporin)
Heterogeneity: Chi2 = 17.92, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 3.70 (P = 0.00022)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 4 Stratified analysis, by studies reporting 12 month data
Outcome: 8 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies reporting less than 12 month data
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Subtotal (95% CI) 25 32 1.3 % 1.49 [ 0.57, 3.89 ]
Total events: 7 (tacrolimus), 6 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
2 Studies reporting 12 month data
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Subtotal (95% CI) 1548 1551 98.7 % 0.64 [ 0.55, 0.73 ]
Total events: 245 (tacrolimus), 386 (cyclosporin)
Heterogeneity: Chi2 = 51.47, df = 11 (P<0.00001); I2 =79%
Test for overall effect: Z = 6.31 (P < 0.00001)
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 5.1. Comparison 5 Stratified analysis, by studies confined to patients with hepatitis C virus,
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Subtotal (95% CI) 63 65 5.3 % 0.83 [ 0.44, 1.56 ]
Total events: 13 (tacrolimus), 16 (cyclosporin)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
2 Studies including hepatitis C virus and other diagnoses
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Subtotal (95% CI) 1836 1849 94.7 % 0.85 [ 0.73, 0.99 ]
Total events: 241 (tacrolimus), 286 (cyclosporin)
Heterogeneity: Chi2 = 11.32, df = 13 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.03 (P = 0.042)
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Subtotal (95% CI) 63 65 5.6 % 0.69 [ 0.40, 1.19 ]
Total events: 15 (tacrolimus), 22 (cyclosporin)
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.33 (P = 0.18)
2 Studies including hepatitis C virus and other diagnoses
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Subtotal (95% CI) 1836 1849 94.4 % 0.79 [ 0.69, 0.90 ]
Total events: 289 (tacrolimus), 370 (cyclosporin)
Heterogeneity: Chi2 = 15.77, df = 13 (P = 0.26); I2 =18%
Test for overall effect: Z = 3.39 (P = 0.00070)
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 3 Acute rejection
Study or subgroup tacrolimusTreatment cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Subtotal (95% CI) 63 65 3.1 % 0.63 [ 0.38, 1.02 ]
Total events: 17 (tacrolimusTreatment), 28 (cyclosporin)
Heterogeneity: Chi2 = 0.70, df = 1 (P = 0.40); I2 =0.0%
Test for overall effect: Z = 1.87 (P = 0.062)
2 Studies including hepatitis C virus and other diagnoses
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Subtotal (95% CI) 1822 1836 96.9 % 0.83 [ 0.77, 0.89 ]
Total events: 711 (tacrolimusTreatment), 860 (cyclosporin)
Heterogeneity: Chi2 = 18.24, df = 13 (P = 0.15); I2 =29%
Test for overall effect: Z = 5.16 (P < 0.00001)
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimusTreatment), 888 (cyclosporin)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Zervos 1998 0/25 1/24 0.8 % 0.32 [ 0.01, 7.50 ]
Subtotal (95% CI) 25 24 0.8 % 0.32 [ 0.01, 7.50 ]
Total events: 0 (tacrolimus), 1 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
2 Studies including hepatitis C virus and other diagnoses
European Study 1994 2/264 14/265 7.1 % 0.14 [ 0.03, 0.62 ]
Fisher 1998 0/49 1/50 0.8 % 0.34 [ 0.01, 8.15 ]
Fung 1991 8/41 12/40 6.2 % 0.65 [ 0.30, 1.42 ]
Greig 2003 4/71 7/72 3.5 % 0.58 [ 0.18, 1.89 ]
Kelly 2004 5/42 24/93 7.6 % 0.46 [ 0.19, 1.13 ]
Klupp 1999 5/40 9/40 4.6 % 0.56 [ 0.20, 1.51 ]
Muehlbacher 2001 39/313 42/307 21.5 % 0.91 [ 0.61, 1.37 ]
Therapondos 2002 0/20 3/20 1.8 % 0.14 [ 0.01, 2.60 ]
Timmermann 2002 4/65 10/69 4.9 % 0.42 [ 0.14, 1.29 ]
U. S. Study 1994 43/263 82/266 41.4 % 0.53 [ 0.38, 0.74 ]
Subtotal (95% CI) 1168 1222 99.2 % 0.58 [ 0.47, 0.71 ]
Total events: 110 (tacrolimus), 204 (cyclosporin)
Heterogeneity: Chi2 = 10.17, df = 9 (P = 0.34); I2 =11%
Test for overall effect: Z = 5.06 (P < 0.00001)
Total (95% CI) 1193 1246 100.0 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
0.01 0.1 1 10 100
Favours tacrolimus Favours cyclosporin
69Cyclosporin versus tacrolimus for liver transplanted patients (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 5.5. Comparison 5 Stratified analysis, by studies confined to patients with hepatitis C virus,
Outcome 5 Post transplant lymphoproliferative disease.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 5 Post transplant lymphoproliferative disease
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Zervos 1998 0/25 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 25 24 0.0 [ 0.0, 0.0 ]
Total events: 0 (tacrolimus), 0 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Studies including hepatitis C virus and other diagnoses
Fung 1991 0/40 2/41 0.20 [ 0.01, 4.14 ]
Greig 2003 0/71 0/72 0.0 [ 0.0, 0.0 ]
Kelly 2004 5/92 1/93 5.05 [ 0.60, 42.43 ]
Klupp 1999 1/40 1/40 1.00 [ 0.06, 15.44 ]
Therapondos 2002 0/20 0/20 0.0 [ 0.0, 0.0 ]
U. S. Study 1994 0/263 2/266 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 526 532 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
Total (95% CI) 551 556 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 5.6. Comparison 5 Stratified analysis, by studies confined to patients with hepatitis C virus,
Outcome 6 Patients withdrawn from tacrolimus or cyclosporin.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 5 Stratified analysis, by studies confined to patients with hepatitis C virus
Outcome: 6 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies confined to patients with hepatitis C virus
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Subtotal (95% CI) 63 65 4.0 % 0.43 [ 0.18, 1.02 ]
Total events: 6 (tacrolimus), 15 (cyclosporin)
Heterogeneity: Chi2 = 7.49, df = 1 (P = 0.01); I2 =87%
Test for overall effect: Z = 1.91 (P = 0.056)
2 Studies including hepatitis C virus and other diagnoses
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 1510 1518 96.0 % 0.66 [ 0.57, 0.76 ]
Total events: 246 (tacrolimus), 377 (cyclosporin)
Heterogeneity: Chi2 = 46.49, df = 10 (P<0.00001); I2 =78%
Test for overall effect: Z = 5.87 (P < 0.00001)
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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Analysis 6.1. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 1 Mortality.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 1 Mortality
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomittant azathioprine
Greig 2003 2/71 8/72 2.6 % 0.25 [ 0.06, 1.15 ]
Martin 2004 6/38 8/41 2.6 % 0.81 [ 0.31, 2.12 ]
O’Grady 2002 50/301 72/305 23.8 % 0.70 [ 0.51, 0.97 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Subtotal (95% CI) 430 438 29.3 % 0.69 [ 0.51, 0.92 ]
Total events: 60 (tacrolimus), 89 (cyclosporin)
Heterogeneity: Chi2 = 2.61, df = 3 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.48 (P = 0.013)
2 Concomitant azathioprine (some centres only)
Grazi 2004 34/245 37/250 12.2 % 0.94 [ 0.61, 1.44 ]
Subtotal (95% CI) 245 250 12.2 % 0.94 [ 0.61, 1.44 ]
Total events: 34 (tacrolimus), 37 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.29 (P = 0.77)
3 Concomitant azathioprine with cyclosporin only (some centres)
European Study 1994 46/264 61/265 20.3 % 0.76 [ 0.54, 1.07 ]
Kelly 2004 7/92 9/93 3.0 % 0.79 [ 0.31, 2.02 ]
Muehlbacher 2001 47/313 37/307 12.4 % 1.25 [ 0.83, 1.86 ]
Timmermann 2002 7/72 7/71 2.3 % 0.99 [ 0.36, 2.67 ]
U. S. Study 1994 31/263 33/266 10.9 % 0.95 [ 0.60, 1.50 ]
Subtotal (95% CI) 1004 1002 48.9 % 0.94 [ 0.76, 1.16 ]
Total events: 138 (tacrolimus), 147 (cyclosporin)
Heterogeneity: Chi2 = 3.58, df = 4 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
4 Concomitant mycophenolate mofetil
Fisher 1998 1/49 2/50 0.7 % 0.51 [ 0.05, 5.45 ]
Klupp 1999 2/40 3/40 1.0 % 0.67 [ 0.12, 3.78 ]
Stegall 1997 4/35 2/36 0.7 % 2.06 [ 0.40, 10.52 ]
Subtotal (95% CI) 124 126 2.3 % 1.02 [ 0.37, 2.80 ]
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Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 7 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 1.27, df = 2 (P = 0.53); I2 =0.0%
Test for overall effect: Z = 0.03 (P = 0.97)
5 No concomitant azathioprine or mycopholic mofetil
Fung 1991 3/41 7/40 2.4 % 0.42 [ 0.12, 1.50 ]
Rolles 1999 5/30 7/34 2.2 % 0.81 [ 0.29, 2.28 ]
Zervos 1998 7/25 8/24 2.7 % 0.84 [ 0.36, 1.96 ]
Subtotal (95% CI) 96 98 7.3 % 0.69 [ 0.39, 1.24 ]
Total events: 15 (tacrolimus), 22 (cyclosporin)
Heterogeneity: Chi2 = 0.88, df = 2 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 1899 1914 100.0 % 0.85 [ 0.73, 0.99 ]
Total events: 254 (tacrolimus), 302 (cyclosporin)
Heterogeneity: Chi2 = 11.33, df = 15 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 2.11 (P = 0.035)
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Analysis 6.2. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 2 Graft loss.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 2 Graft loss
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Studies with concomittant azathioprine
Greig 2003 2/71 10/72 2.5 % 0.20 [ 0.05, 0.89 ]
Martin 2004 7/38 10/41 2.5 % 0.76 [ 0.32, 1.78 ]
O’Grady 2002 58/301 88/305 22.4 % 0.67 [ 0.50, 0.89 ]
Therapondos 2002 2/20 1/20 0.3 % 2.00 [ 0.20, 20.33 ]
Subtotal (95% CI) 430 438 27.6 % 0.65 [ 0.49, 0.84 ]
Total events: 69 (tacrolimus), 109 (cyclosporin)
Heterogeneity: Chi2 = 3.44, df = 3 (P = 0.33); I2 =13%
Test for overall effect: Z = 3.21 (P = 0.0013)
2 Concomitant azathioprine (some centres only)
Grazi 2004 29/245 27/250 6.8 % 1.10 [ 0.67, 1.80 ]
Subtotal (95% CI) 245 250 6.8 % 1.10 [ 0.67, 1.80 ]
Total events: 29 (tacrolimus), 27 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.36 (P = 0.72)
3 Concomitant azathioprine with cyclosporine only (some centres)
European Study 1994 60/264 74/265 18.9 % 0.81 [ 0.61, 1.09 ]
Kelly 2004 7/92 13/93 3.3 % 0.54 [ 0.23, 1.30 ]
Muehlbacher 2001 53/313 52/307 13.4 % 1.00 [ 0.71, 1.42 ]
Timmermann 2002 10/72 13/71 3.4 % 0.76 [ 0.36, 1.62 ]
U. S. Study 1994 48/263 55/266 14.0 % 0.88 [ 0.62, 1.25 ]
Subtotal (95% CI) 1004 1002 53.0 % 0.86 [ 0.72, 1.03 ]
Total events: 178 (tacrolimus), 207 (cyclosporin)
Heterogeneity: Chi2 = 2.03, df = 4 (P = 0.73); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
4 Concomitant mycophenolate mofetil
Fisher 1998 3/49 5/50 1.3 % 0.61 [ 0.15, 2.42 ]
Klupp 1999 0/40 4/40 1.2 % 0.11 [ 0.01, 2.00 ]
Stegall 1997 5/35 3/36 0.8 % 1.71 [ 0.44, 6.64 ]
Subtotal (95% CI) 124 126 3.2 % 0.69 [ 0.30, 1.60 ]
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Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 8 (tacrolimus), 12 (cyclosporin)
Heterogeneity: Chi2 = 3.29, df = 2 (P = 0.19); I2 =39%
Test for overall effect: Z = 0.86 (P = 0.39)
5 No concomitant azathioprine or mycophenolate mofetil
Fung 1991 4/41 12/40 3.1 % 0.33 [ 0.11, 0.92 ]
Rolles 1999 8/30 13/34 3.1 % 0.70 [ 0.34, 1.45 ]
Zervos 1998 8/25 12/24 3.1 % 0.64 [ 0.32, 1.29 ]
Subtotal (95% CI) 96 98 9.4 % 0.55 [ 0.35, 0.88 ]
Total events: 20 (tacrolimus), 37 (cyclosporin)
Heterogeneity: Chi2 = 1.54, df = 2 (P = 0.46); I2 =0.0%
Test for overall effect: Z = 2.53 (P = 0.011)
Total (95% CI) 1899 1914 100.0 % 0.78 [ 0.68, 0.89 ]
Total events: 304 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 16.15, df = 15 (P = 0.37); I2 =7%
Test for overall effect: Z = 3.59 (P = 0.00033)
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Analysis 6.3. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 3 Acute rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 3 Acute rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 25/71 31/72 3.5 % 0.82 [ 0.54, 1.24 ]
Martin 2004 11/38 16/41 1.7 % 0.74 [ 0.40, 1.39 ]
O’Grady 2002 143/301 179/305 20.1 % 0.81 [ 0.70, 0.94 ]
Therapondos 2002 8/20 3/20 0.3 % 2.67 [ 0.82, 8.62 ]
Subtotal (95% CI) 430 438 25.6 % 0.83 [ 0.72, 0.95 ]
Total events: 187 (tacrolimus), 229 (cyclosporin)
Heterogeneity: Chi2 = 4.04, df = 3 (P = 0.26); I2 =26%
Test for overall effect: Z = 2.63 (P = 0.0087)
2 Concomitant azathioprine (some centres only)
Grazi 2004 12/245 18/250 2.0 % 0.68 [ 0.33, 1.38 ]
Subtotal (95% CI) 245 250 2.0 % 0.68 [ 0.33, 1.38 ]
Total events: 12 (tacrolimus), 18 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.29)
3 Concomitant azathioprine with cyclosporin only (some centres)
European Study 1994 115/264 142/265 16.0 % 0.81 [ 0.68, 0.97 ]
Kelly 2004 38/92 49/93 5.5 % 0.78 [ 0.57, 1.07 ]
Muehlbacher 2001 119/313 135/307 15.4 % 0.86 [ 0.72, 1.05 ]
Timmermann 2002 24/65 32/69 3.5 % 0.80 [ 0.53, 1.20 ]
U. S. Study 1994 154/265 173/266 19.5 % 0.89 [ 0.78, 1.02 ]
Subtotal (95% CI) 999 1000 59.9 % 0.85 [ 0.78, 0.93 ]
Total events: 450 (tacrolimus), 531 (cyclosporin)
Heterogeneity: Chi2 = 1.17, df = 4 (P = 0.88); I2 =0.0%
Test for overall effect: Z = 3.62 (P = 0.00029)
4 Concomitant mycophenolate mofetil
Fisher 1998 5/49 2/50 0.2 % 2.55 [ 0.52, 12.53 ]
Klupp 1999 18/40 30/40 3.4 % 0.60 [ 0.41, 0.88 ]
Stegall 1997 11/26 15/32 1.5 % 0.90 [ 0.50, 1.61 ]
Subtotal (95% CI) 115 122 5.1 % 0.77 [ 0.56, 1.06 ]
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Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 34 (tacrolimus), 47 (cyclosporin)
Heterogeneity: Chi2 = 4.10, df = 2 (P = 0.13); I2 =51%
Test for overall effect: Z = 1.58 (P = 0.11)
5 No concomitant azathioprine or mycophenolate
Fung 1991 19/41 29/33 3.6 % 0.53 [ 0.37, 0.75 ]
Rolles 1999 20/30 22/34 2.3 % 1.03 [ 0.72, 1.47 ]
Zervos 1998 6/25 12/24 1.4 % 0.48 [ 0.21, 1.07 ]
Subtotal (95% CI) 96 91 7.3 % 0.68 [ 0.53, 0.86 ]
Total events: 45 (tacrolimus), 63 (cyclosporin)
Heterogeneity: Chi2 = 8.01, df = 2 (P = 0.02); I2 =75%
Test for overall effect: Z = 3.13 (P = 0.0017)
Total (95% CI) 1885 1901 100.0 % 0.82 [ 0.77, 0.88 ]
Total events: 728 (tacrolimus), 888 (cyclosporin)
Heterogeneity: Chi2 = 20.10, df = 15 (P = 0.17); I2 =25%
Test for overall effect: Z = 5.43 (P < 0.00001)
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Analysis 6.4. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 4 Steroid-resistent rejection.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 4 Steroid-resistent rejection
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 4/71 7/72 3.5 % 0.58 [ 0.18, 1.89 ]
Therapondos 2002 0/20 3/20 1.8 % 0.14 [ 0.01, 2.60 ]
Subtotal (95% CI) 91 92 5.3 % 0.43 [ 0.15, 1.26 ]
Total events: 4 (tacrolimus), 10 (cyclosporin)
Heterogeneity: Chi2 = 0.79, df = 1 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
2 Concomitant azathioprine with cyclosporin only (some centres only)
European Study 1994 2/264 14/265 7.1 % 0.14 [ 0.03, 0.62 ]
Kelly 2004 5/42 24/93 7.6 % 0.46 [ 0.19, 1.13 ]
Muehlbacher 2001 39/313 42/307 21.5 % 0.91 [ 0.61, 1.37 ]
Timmermann 2002 4/65 10/69 4.9 % 0.42 [ 0.14, 1.29 ]
U. S. Study 1994 43/263 82/266 41.4 % 0.53 [ 0.38, 0.74 ]
Subtotal (95% CI) 947 1000 82.4 % 0.58 [ 0.46, 0.74 ]
Total events: 93 (tacrolimus), 172 (cyclosporin)
Heterogeneity: Chi2 = 9.01, df = 4 (P = 0.06); I2 =56%
Test for overall effect: Z = 4.52 (P < 0.00001)
3 Concomitant mycophenolate mofetil
Fisher 1998 0/49 1/50 0.8 % 0.34 [ 0.01, 8.15 ]
Klupp 1999 5/40 9/40 4.6 % 0.56 [ 0.20, 1.51 ]
Subtotal (95% CI) 89 90 5.3 % 0.53 [ 0.20, 1.37 ]
Total events: 5 (tacrolimus), 10 (cyclosporin)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.32 (P = 0.19)
4 No concomitant azathioprine or mycophenolate mofetil
Fung 1991 8/41 12/40 6.2 % 0.65 [ 0.30, 1.42 ]
Zervos 1998 0/25 1/24 0.8 % 0.32 [ 0.01, 7.50 ]
Subtotal (95% CI) 66 64 6.9 % 0.61 [ 0.29, 1.31 ]
Total events: 8 (tacrolimus), 13 (cyclosporin)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
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Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Test for overall effect: Z = 1.26 (P = 0.21)
Total (95% CI) 1193 1246 100.0 % 0.57 [ 0.46, 0.71 ]
Total events: 110 (tacrolimus), 205 (cyclosporin)
Heterogeneity: Chi2 = 10.32, df = 10 (P = 0.41); I2 =3%
Test for overall effect: Z = 5.10 (P < 0.00001)
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Analysis 6.5. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 5 Dialysis (de-novo requirement post-transplantation).
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 5 Dialysis (de-novo requirement post-transplantation)
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 7/71 5/72 1.42 [ 0.47, 4.26 ]
Therapondos 2002 1/20 0/20 3.00 [ 0.13, 69.52 ]
Subtotal (95% CI) 91 92 1.56 [ 0.56, 4.39 ]
Total events: 8 (tacrolimus), 5 (cyclosporin)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 0.85 (P = 0.40)
2 Concomitant azathioprine with cyclosporin only (some centres only)
U. S. Study 1994 0/263 0/266 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 263 266 0.0 [ 0.0, 0.0 ]
Total events: 0 (tacrolimus), 0 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
3 Concomitant mycophenolate mofetil
Klupp 1999 2/40 1/40 2.00 [ 0.19, 21.18 ]
Subtotal (95% CI) 40 40 2.00 [ 0.19, 21.18 ]
Total events: 2 (tacrolimus), 1 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
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Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
4 No concomitant azathioprine or mycophenolate mofetil
Fung 1991 1/40 1/41 1.03 [ 0.07, 15.83 ]
Subtotal (95% CI) 40 41 1.03 [ 0.07, 15.83 ]
Total events: 1 (tacrolimus), 1 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.99)
Total (95% CI) 434 439 1.55 [ 0.64, 3.78 ]
Total events: 11 (tacrolimus), 7 (cyclosporin)
Heterogeneity: Chi2 = 0.33, df = 3 (P = 0.95); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 6.6. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 6 Diabetes mellitus: initially diagnosed after transplantation.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 6 Diabetes mellitus: initially diagnosed after transplantation
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 17/71 20/72 8.2 % 0.86 [ 0.49, 1.50 ]
O’Grady 2002 33/301 14/305 5.7 % 2.39 [ 1.30, 4.37 ]
Therapondos 2002 3/20 0/20 0.2 % 7.00 [ 0.38, 127.32 ]
Subtotal (95% CI) 392 397 14.1 % 1.57 [ 1.06, 2.33 ]
Total events: 53 (tacrolimus), 34 (cyclosporin)
Heterogeneity: Chi2 = 7.32, df = 2 (P = 0.03); I2 =73%
Test for overall effect: Z = 2.24 (P = 0.025)
2 Concomitant azathioprine with cyclosporin only (some centres only)
European Study 1994 177/264 162/265 66.7 % 1.10 [ 0.97, 1.25 ]
Kelly 2004 2/92 2/93 0.8 % 1.01 [ 0.15, 7.02 ]
Muehlbacher 2001 49/313 25/307 10.4 % 1.92 [ 1.22, 3.03 ]
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Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Timmermann 2002 3/65 4/69 1.6 % 0.80 [ 0.19, 3.42 ]
U. S. Study 1994 11/263 5/266 2.1 % 2.23 [ 0.78, 6.32 ]
Subtotal (95% CI) 997 1000 81.6 % 1.22 [ 1.07, 1.40 ]
Total events: 242 (tacrolimus), 198 (cyclosporin)
Heterogeneity: Chi2 = 8.23, df = 4 (P = 0.08); I2 =51%
Test for overall effect: Z = 3.02 (P = 0.0026)
3 Concomitant mycophenolate mofetil
Fisher 1998 7/49 7/50 2.9 % 1.02 [ 0.39, 2.69 ]
Klupp 1999 3/40 3/40 1.2 % 1.00 [ 0.21, 4.66 ]
Stegall 1997 1/25 0/33 0.2 % 3.92 [ 0.17, 92.43 ]
Subtotal (95% CI) 114 123 4.3 % 1.14 [ 0.52, 2.49 ]
Total events: 11 (tacrolimus), 10 (cyclosporin)
Heterogeneity: Chi2 = 0.66, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.32 (P = 0.75)
Total (95% CI) 1503 1520 100.0 % 1.27 [ 1.12, 1.44 ]
Total events: 306 (tacrolimus), 242 (cyclosporin)
Heterogeneity: Chi2 = 17.92, df = 10 (P = 0.06); I2 =44%
Test for overall effect: Z = 3.70 (P = 0.00022)
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Analysis 6.7. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 7 Post transplant lymphoproliferative disease.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 7 Post transplant lymphoproliferative disease
Study or subgroup tacrolimus cyclosporin Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 0/71 0/72 0.0 [ 0.0, 0.0 ]
Therapondos 2002 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 91 92 0.0 [ 0.0, 0.0 ]
Total events: 0 (tacrolimus), 0 (cyclosporin)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
2 Concomitant azathioprine with cyclosporin only (some centres only)
Kelly 2004 5/92 1/93 5.05 [ 0.60, 42.43 ]
U. S. Study 1994 0/263 2/266 0.20 [ 0.01, 4.19 ]
Subtotal (95% CI) 355 359 1.59 [ 0.42, 6.02 ]
Total events: 5 (tacrolimus), 3 (cyclosporin)
Heterogeneity: Chi2 = 2.91, df = 1 (P = 0.09); I2 =66%
Test for overall effect: Z = 0.68 (P = 0.50)
3 Concomitant mycophenolate mofetil
Klupp 1999 1/40 1/40 1.00 [ 0.06, 15.44 ]
Subtotal (95% CI) 40 40 1.00 [ 0.06, 15.44 ]
Total events: 1 (tacrolimus), 1 (cyclosporin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
4 No concomitant azathioprine or mycophenolate mofetil
Fung 1991 0/40 2/41 0.20 [ 0.01, 4.14 ]
Zervos 1998 0/25 0/24 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 65 65 0.20 [ 0.01, 4.14 ]
Total events: 0 (tacrolimus), 2 (cyclosporin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.03 (P = 0.30)
Total (95% CI) 551 556 1.01 [ 0.36, 2.86 ]
Total events: 6 (tacrolimus), 6 (cyclosporin)
Heterogeneity: Chi2 = 4.36, df = 3 (P = 0.22); I2 =31%
Test for overall effect: Z = 0.02 (P = 0.98)
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Analysis 6.8. Comparison 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil,
Outcome 8 Patients withdrawn from tacrolimus or cyclosporin.
Review: Cyclosporin versus tacrolimus for liver transplanted patients
Comparison: 6 Stratified analysis, by concomitant azathioprine or mycophenolate mofetil
Outcome: 8 Patients withdrawn from tacrolimus or cyclosporin
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Concomitant azathioprine
Greig 2003 7/71 7/72 1.8 % 1.01 [ 0.37, 2.74 ]
Martin 2004 6/38 4/41 1.0 % 1.62 [ 0.49, 5.30 ]
O’Grady 2002 33/301 57/305 14.4 % 0.59 [ 0.39, 0.87 ]
Therapondos 2002 2/18 4/19 1.0 % 0.53 [ 0.11, 2.54 ]
Subtotal (95% CI) 428 437 18.2 % 0.68 [ 0.48, 0.96 ]
Total events: 48 (tacrolimus), 72 (cyclosporin)
Heterogeneity: Chi2 = 3.30, df = 3 (P = 0.35); I2 =9%
Test for overall effect: Z = 2.22 (P = 0.027)
2 Concomitant azathioprine with cyclosporin only (some centres only)
European Study 1994 76/264 64/265 16.3 % 1.19 [ 0.90, 1.59 ]
Kelly 2004 21/91 43/90 11.0 % 0.48 [ 0.31, 0.74 ]
Muehlbacher 2001 4/310 18/305 4.6 % 0.22 [ 0.07, 0.64 ]
U. S. Study 1994 83/263 102/266 25.9 % 0.82 [ 0.65, 1.04 ]
Subtotal (95% CI) 928 926 57.8 % 0.81 [ 0.69, 0.96 ]
Total events: 184 (tacrolimus), 227 (cyclosporin)
Heterogeneity: Chi2 = 18.23, df = 3 (P = 0.00039); I2 =84%
Test for overall effect: Z = 2.48 (P = 0.013)
3 Concomitant mycophenolate mofetil
Fisher 1998 7/48 10/49 2.5 % 0.71 [ 0.30, 1.72 ]
Klupp 1999 5/40 19/40 4.8 % 0.26 [ 0.11, 0.64 ]
Stegall 1997 7/25 6/32 1.3 % 1.49 [ 0.57, 3.89 ]
Subtotal (95% CI) 113 121 8.7 % 0.58 [ 0.36, 0.96 ]
Total events: 19 (tacrolimus), 35 (cyclosporin)
Heterogeneity: Chi2 = 7.04, df = 2 (P = 0.03); I2 =72%
Test for overall effect: Z = 2.14 (P = 0.032)
4 No concomitant azathioprine or mycophenolate mofetil
Fung 1991 1/79 47/75 12.3 % 0.02 [ 0.00, 0.14 ]
Zervos 1998 0/25 11/24 3.0 % 0.04 [ 0.00, 0.67 ]
Subtotal (95% CI) 104 99 15.3 % 0.02 [ 0.00, 0.12 ]
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(. . . Continued)
Study or subgroup tacrolimus cyclosporin Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Total events: 1 (tacrolimus), 58 (cyclosporin)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 4.56 (P < 0.00001)
Total (95% CI) 1573 1583 100.0 % 0.65 [ 0.57, 0.74 ]
Total events: 252 (tacrolimus), 392 (cyclosporin)
Heterogeneity: Chi2 = 53.32, df = 12 (P<0.00001); I2 =77%
Test for overall effect: Z = 6.14 (P < 0.00001)
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A P P E N D I C E S
Appendix 1. Search Strategies
Database Timespan of search Search strategy
TheCochraneHepato-BiliaryGroupCon-
trolled Trials Register
August 2005. (c*closporin* OR neoral* OR sandimmun*)AND (tacrolimus
OR prograf OR FK506) AND (’liver transplant*’)
Cochrane Centrale Register of Controlled
Trials in The Cochrane Library
Issue 3, 2005. #1 MeSH descriptor Cyclosporine explode all trees in MeSH
products
#2 c*closporin* OR neoral* OR sandimmun* in All Fields in all
products
#3 (#1 OR #2)
#4MeSHdescriptor Tacrolimus explode all trees inMeSH prod-
ucts
#5 tacrolimusORprografORFK506 inAll Fields in all products
#6 (#4 OR #5)
#7 MeSH descriptor Liver Transplantation explode all trees in
MeSH products
#8 liver transplant* in All Fields in all products
#9 (#7 OR #8)
#10 (#3 AND #6 AND #9)
MEDLINE (WinSPIRS 5.0) 1950 to Aug 2005. #1 explode “Cyclosporine”/all subheadings
#2 c*closporin* or neoral* or sandimmun*
#3 #1 or #2
#4 explode “Tacrolimus”/all subheadings
#5 tacrolimus or prograf or FK506
#6 #4 or #5
#7 explode “Liver-Transplantation”/all subheadings
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(Continued)
#8 liver transplant*
#9 #7 or #8
#10 #3 and #6 and #9
#11 random* or placebo* or blind* or meta-analysis
#12 #10 and #11
EMBASE (WinSPIRS 5.0) 1980 to Aug 2005. #1 explode “cyclosporin”/all subheadings
#2 c*closporin* or neoral* or sandimmun*
#3 #1 or #2
#4 explode “tsukubaenolide”/all subheadings
#5 tacrolimus or prograf or FK506 or tsukubaenolide
#6 #4 or #5
#7 explode “liver-transplantation”/all subheadings
#8 liver transplant*
#9 #7 or #8
#10 #3 and #6 and #9
#11 random* or placebo* or blind* or meta-analysis
#12 #10 and #11
Science Citation Index Expanded (http://
portal.isiknowledge.com/portal.cgi?
DestApp=WOS&Func=Frame)
1945 to Aug 2005. #1 TS=(c*closporin* OR neoral* OR sandimmun*)
#2 TS=(tacrolimus OR prograf OR FK506)
#3 TS=(liver transplant*)
#4 #3 AND #2 AND #1
#5 TS=(random* or placebo* or blind* or meta-analysis)
#6 #5 AND #4
WH A T ’ S N E W
Last assessed as up-to-date: 23 August 2006.
17 October 2008 Amended Converted to new review format.
H I S T O R Y
Protocol first published: Issue 1, 2005
Review first published: Issue 4, 2006
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C O N T R I B U T I O N S O F A U T H O R S
All authors contributed to the design of the protocol. V McAlister and E Haddad evaluated whether the trials fulfilled the inclusion
criteria. E Renouf hand searched reference sections of the reports for other randomised clinical trails, and prepared blinded copies of all
selected reports. V McAlister and E Haddad independently extracted data. R Malthaner adjudicated differences. All authors reviewed
trial selection and data extraction. V McAlister wrote to investigators and to the sponsoring companies of included trials to ask for data
that are not presented in the published reports. V McAlister and E Haddad performed all meta-analyses in RevMan. LL Gluud and M
Kjaer performed additional blinded statistical analyses including meta-regression and regression analyses of funnel plot asymmetry. All
authors contributed to and approved the review.
D E C L A R A T I O N S O F I N T E R E S T
V McAlister has taken part in clinical trials of tacrolimus and cyclosporin in liver and kidney transplantation. He has received grants-
in-aid for laboratory research from Sandoz (Novartis) and Fujisawa (Astelis).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Liver Transplantation [mortality]; Cyclosporine [adverse effects; ∗therapeutic use]; Graft Rejection [mortality; ∗prevention & control];
Graft Survival; Immunosuppressive Agents [adverse effects; ∗therapeutic use]; Randomized Controlled Trials as Topic; Tacrolimus
[adverse effects; ∗therapeutic use]; Time Factors
MeSH check words
Humans
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